

Registration : [www.meeting-com.ch](http://www.meeting-com.ch)

# Final Program



## 47th Annual Meeting Swiss Society of Nephrology

Congress Center Basel  
December 3-4, 2015

Schweizerische Gesellschaft für Nephrologie  
Société Suisse de Néphrologie  
Società Svizzera di Nefrologia

**NEPHRO**  
SWISS SOCIETY OF NEPHROLOGY

[www.swissnephrology.ch](http://www.swissnephrology.ch)

Early Symposia  
Basics in Nephrology  
Pflege in der Nephrologie  
December 2, 2015



Visit us at **SGN-SSN 2015**



**FRESENIUS  
MEDICAL CARE**

Fresenius Medical Care (Schweiz) AG · Aawasserstrasse 2 · 6370 Oberdorf NW  
Telefon +41 (0)41 619 50 50 · Fax +41 (0)41 619 50 80 · [info.ch@fmc-ag.com](mailto:info.ch@fmc-ag.com) · [www.fresenius.ch](http://www.fresenius.ch)

Innovating the future of dialysis.

# Invitation 2015

Dear Colleagues,

It is with great pleasure that we invite you to Basel for the 47th annual meeting. We hope you will not only find time to enjoy the meeting, but also some of the cultural excellence of our city!

The board of the Swiss Society of nephrology gave the mandate to the organizing committee to put an emphasis on kidney transplantation. This was in particular applied to the special satellite symposium of nursing science and the satellite CME symposium – both taking place on Wednesday afternoon. In the first symposium frailty in kidney transplantation and self-management of the patients are discussed with a small excursion into robotics in nursing. In the CME symposium key aspects of kidney transplantation are presented—starting from the pre-transplant immunological assessment and ending in the long-term management of the transplanted patient.

The actual meeting covers four big topics in Nephrology, i.e. basic science, clinical nephrology, dialysis and transplantation. Excellent speakers from abroad and within Switzerland will update you on the latest achievements. To provide more young scientists & nephrologists a platform to present their work, the oral presentation sessions were prolonged, and the 'forgotten' poster walk will have its revival. Please join one of the moderators on Thursday afternoon on their way through the poster exhibition. We are sure you will find interesting presentations and lively discussions!

Furthermore, we want to stimulate you to attend the satellite symposia and also the general assembly of our society. Last but not least we hope that you will not miss the final session summarizing the best studies in Nephrology in 2015!



Prof. Jürg Steiger, Basel  
Congress president SGN-SSN 2015

# Table of contents

Invitation 2015	3
Organization	5
General information	6
Program at a glance	9
Scientific Program – Pflege in der Nephrologie	12
Scientific Program – Basics in Nephrology	13
Scientific Program	14
Speakers / Moderators	27
Poster presentations	36
Congress Dinner	55
Exhibitors	57
Sponsored symposia in alphabetical order	58
Sponsors	60
SGN-SSN congress 2016 & 2017	62

# Organization

## Congress President

Jürg Steiger, Basel

## Local Organising Committee

Michael Dickenmann, Basel  
Stefan Schaub, Basel

## Scientific Committee

Patrizia Amico, Basel  
Olivier Bonny, Lausanne  
Olivier Devuyst, Zürich  
Stefan Farese, Solothurn  
Daniel Fuster, Bern  
Patricia Hirt-Minkowski, Basel  
Helmut Hopfer, Basel  
Min-Jeong Kim, Basel

## Board of the SGN-SSN

### **President**

Jürg Steiger, Universitätsspital, Basel

### **President-elect**

Pierre-Yves Martin, HUG, Genève

### **Secretary**

Olivier Bonny, CHUV, Lausanne

### **Treasurer**

Patrick Wilson, Hôpital du Jura, Delémont

### **FMH-Delegate**

Ann-Kathrin Schwarzkopf, Salem Spital, Bern

### **Pediatric Nephrologist**

Thomas J. Neuhaus, Kinderspital LUKS, Luzern

### **Dialysis Commission**

Denes Kiss, Kantonsspital, Liestal

### **Board Members**

Andreas Bock, Kantonsspital, Aarau  
Olivier Devuyst, Institute of Physiology, Zürich  
Daniel Fuster, Inselspital, Bern  
Luca Gabutti, Ospedale Regionale, Locarno

# General information

## Congress venue

### Congress Center Basel

Messeplatz 21, 4058 Basel, [www.congress.ch](http://www.congress.ch)

## Registration & congress secretariat

### Meeting.com Congress organisation

Rue des Pâquis 1, CP 100, CH-1033 Cheseaux-sur-Lausanne

Online registration on: [www.meeting-com.ch](http://www.meeting-com.ch)

T +41 21 312 9261 – F +41 21 312 9263 – E [info@meeting-com.ch](mailto:info@meeting-com.ch)

Onsite registration also possible (onsite fee)

## Registration fee for congress

### Early fee

(before Nov. 1, 2015)

### Late fee

(Nov. 2-Nov. 29, 2015)

### Onsite fee

(From Nov. 30, 2015)

Member SGN-SSN

CHF 230.00

CHF 270.00

CHF 300.00

Non-member

CHF 280.00

CHF 320.00

CHF 360.00

Trainees/ Residents/  
Students\*

CHF 150.00

CHF 180.00

CHF 210.00

*NCCR-Member*

*CHF 150.00*

*CHF 180.00*

*CHF 210.00*

The registration fee includes: access to the scientific sessions, congress documents and lunches. The Congress Dinner is not included and has to be booked separately when registering (CHF 90.00). Places are limited and a reservation is required.

\*In order to benefit from the reduced fee, students or residents are required to send a document confirming their status to the SGN-SSN 2015 Congress Management by fax or scanned within 7 days from the date of registration.

## Registration fee for parallel symposia

### Early fee

(before Nov. 1, 2015)

### Late fee

(Nov. 2-Nov. 29, 2015)

### Onsite fee

(From Nov. 30, 2015)

Basics in Nephrology

CHF 100.00

CHF 120.00

CHF 150.00

Pflege in der Nephrologie

CHF 80.00

CHF 100.00

CHF 120.00

Separate registration is required using the online-registration on [www.meeting-com](http://www.meeting-com).

## Payment

A confirmation is sent by email together with the banking details for the payment upon registration. Paying by credit card when registering online is possible, and mandatory for any registration abroad.

## General information

- Congress management** Meeting-com Congress Organisation  
Mrs Sabine Gisler  
Rue des Pâquis 1, CP 100, 1033 Cheseaux-sur-Lausanne  
T +41 21 312 9161, F +41 21 312 9263  
[sabine.gisler@meeting-com.ch](mailto:sabine.gisler@meeting-com.ch), [www.meeting-com.ch](http://www.meeting-com.ch)
- Certificate of participation** The certificate of participation will be available online and downloadable after the congress. A link will be sent to all participants accordingly.
- Cancellation** Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the «early bird» time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.
- Industrial exhibition** An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.
- Hotel booking** Hotel reservation possible with Basel Tourismus on [www.basel.com](http://www.basel.com).
- Abstracts** The abstracts must be submitted until September 20, 2015, only via Internet on: [www.swissnephrology.ch](http://www.swissnephrology.ch). The deadline will not be extended. The abstracts accepted as poster will be presented in the poster exhibition.
- Dimensions of posters: height 120 cm x width 90 cm.
- The highest rated poster in each category of
- Clinical Nephrology / Hypertension / Mineral / Electrolytes
  - Basic Science / Genetics / Experimental Nephrology
  - Transplantation
  - Hemodialysis HD / Peritoneal dialysis PD

## General information

will receive the Poster Prize Award (Sponsored by Roche) during the Congress Dinner on December 3, 2015.

The Scientific Committee will select a number of abstracts which will be presented as oral presentations.

Speaking time: 8 min and 2 min discussion.

### Confirmation

Scientific contributions (oral presentations and posters) will be reviewed and confirmed by e-mail in October, 2015.

**Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee.**

### Credits

Credits points will be given by the following societies:

#### SGN-SSN Congress, December 3-4, 2015

SGN-SSN: 12 credit points

SGIM / SGAM: 7 credit points

#### Basics in Nephrology, December 2, 2015

SGN-SSN: 4 credit points

SGIM / SGAM: 4 credit points

### Language

Lectures in English, discussion in German, French or English.  
**The Symposium «Pflege in der Nephrologie» will be held in German.**



# Program at a glance

## Wednesday, December 2, 2015

	Special Satellite Symposium Pflege in der Nephrologie	Special CME Symposium Basics in Nephrology
Time	Room A-Singapore	Room B-Sydney
12.30-13.30	Registration	
13.30-15.30	Pflege in der Nephrologie	Plenary session
15.30-16.00	Kaffeepause	Coffee break
16.00-18.00	Pflege in der Nephrologie	Plenary session
18.00	Ende des Symposiums	End of Basics in Nephrology Course

# Program at a glance

## Thursday, December 3, 2015

Time	Room A-Singapore	Room B-Sydney
07.30-10.00	Registration	
10.00-10.05	Welcome Address	
10.05-11.00	State of the Art Lectures	
11.00-11.30	Coffee break – Visit of the Exhibition	
11.30-12.45	Oral Parallel Presentations Clinical Nephrology	Oral Parallel Presentations Basic Science
12.45-13.00	Short break	
13.00-13.45	Satellite Lunch Symposium Sponsored by <b>OTSUKA</b>	Satellite Lunch Symposium Sponsored by <b>BAXTER</b>
13.45-14.30	Standing lunch at the Exhibition	
14.30-15.30	Posterwalk in the Exhibition	
15.30-16.00	Coffee break – Visit of the Exhibition	
16.00-17.00	Parallel Symposium Clinical Nephrology	Parallel Symposium NCCR / Basic Science
17.00-17.15	Short break	
17.15-18.15	Satellite Symposium Sponsored by <b>NOVARTIS</b>	
From 19.30	Poster Prize Awards (Sponsored by <b>ROCHE</b> ) & Congress Dinner	

# Program at a glance

## Friday December 4, 2015

Time	Room A-Singapore	Room B-Sydney
07.00-08.00	Registration	
08.00-09.30	General assembly SGN-SSN	
09.30-10.00	The Swiss Dialysis Registry	
10.00-10.30	Coffee break – Visit of the Exhibition	
10.30-10.45	SGN-SSN Publication Award 2015	
10.45-11.45	State of the Art Lectures	
11.45-12.00	Break	
12.00-12.45	Satellite Symposium Sponsored by BAXTER	Satellite Symposium Sponsored by VIFOR
12.45-13.00	Break	
13.00-13.45	Satellite Lunch Symposium Sponsored by AMGEN	Satellite Lunch Symposium Sponsored by ASTELLAS
13.45-14.30	Standing lunch at the Exhibition – Poster Viewing	
14.30-15.45	Oral Parallel Presentations Hemodialysis and PD	Oral Parallel Presentations Transplantation
15.45-16.15	Coffee Break – Visit of the Exhibition	
16.15-17.15	The best studies of the last year in Basic Science – Clinical nephrology – HD/PD – Transplantation	
17.15	Farewell	

## **Special Satellite Symposium: Pflege in der Nephrologie / Soins en Néphrologie**

(Symposiumssprache: Deutsch & Englisch)

**Opening the horizon beyond a biomedical perspective:  
frailty and self-management in end-stage renal disease**  
*Chair: Sabina De Geest & Oliver Mauthner, Basel*

- Ab 12.30      Registration
- 13.30-14.05      **Exploring frailty in kidney transplantation: an innovative approach  
to guide clinical practice**  
Oliver Mauthner, Basel; Uyen Huynh-Do, Bern
- 14.10-14.45      **Physical activity, sedentary behavior and its link with frailty  
in kidney transplantation: what clinicians need to know**  
Veerle Claes, Basel
- 14.45-15.20      **Robotics in nursing: is this the future?**  
Sabina De Geest, Basel
- 15.20-15.50      Coffee break at the Fresenius-Amgen booth Nr 17
- 15.50-16.25      **Self-management in daily life: experiences and perspectives  
of kidney transplant recipients**  
(Roundtable discussion with older transplant recipients)
- 16.30-17.05      **Self-management in daily life: prevention of weight gain and support  
of physical exercise in kidney transplantation in daily practice**  
Gabriela Schmid-Mohler, Zürich; Patrizia Zala, Zürich
- 17.10-17.45      **How can nurses support self-management in kidney transplantation?**  
Silvia Hils, Freiburg (DE)
- 17.45-18.00      **Final remarks & End of symposium**

## Satellite CME Symposium: Basics in Nephrology

(Language of symposium: English)

### Renal transplantation in a nutshell: what you need to know about...

*Chair: Felix Burkhalter, Basel*

- |             |   |
|-------------|---|
| From 12.30  | Registration  |
| 13.30-14.00 | <b>Immunological assessment</b><br>Stefan Schaub, Basel           |
| 14.00-14.30 | <b>Surgical procedure</b><br>Thomas Wolff, Basel                  |
| 14.30-15.00 | <b>Immunosuppressive drugs</b><br>Jürg Steiger, Basel             |
| 15.00-15.30 | <b>Acute transplant dysfunction</b><br>Patrizia Amico, Basel      |
| 15.30-16.00 | Coffee break at the Fresenius-Amgen booth Nr 17                   |
| 16.00-16.30 | <b>Allograft histology</b><br>Helmut Hopfer, Basel                |
| 16.30-17.00 | <b>Transplant related infections</b><br>Felix Burkhalter, Basel   |
| 17.00-17.30 | <b>Long-term monitoring and treatment</b><br>Min-Jeong Kim, Basel |
| 17.30-18.00 | <b>Patient selection</b><br>Michael Dickenmann, Basel             |
| 18.00       | <b>End of symposium</b>   |

# Thursday, December 3

## Swiss Society of Nephrology Congress

From 07.30	Registration	
10.00	Opening of the 47 <sup>th</sup> Annual Meeting of the Swiss Society of Nephrology	Room A-Singapore
10.00-10.05	Welcome Address Jürg Steiger, Basel	
10.05-11.00	State of The Art Lectures <i>Chairs: Helmut Hopfer, Basel; Solange Moll, Geneva</i>	Room A-Singapore
10.05-10.30	Membranous Nephropathy: autoantibodies and podocytes Catherine Meyer-Schwesinger, Hamburg (DE)	
10.30 – 11.00	Update on crescentic and rapidly progressive glomerulonephritis: from pathogenesis to treatment Pierre-Louis Tharaux, Paris (F)	
11.00-11.30	Coffee Break – Visit of the Exhibition	Exhibition space
11.30-12.45	Oral Parallel Presentations Clinical Nephrology <i>Chairs: Andreas Fischer, Luzern; Olivier Bonny, Lausanne</i> 6 oral presentations	Room A-Singapore
	Basic Science <i>Chairs: Daniel Fuster, Bern; Olivier Devuyst, Zürich</i> 6 oral presentations	Room B-Sydney
12.45-13.00	Short break	

# Oral communications

## Oral Parallel Presentations

11.30-12.45

**Clinical Nephrology**

**Room A-Singapore**

*Chairs: Andreas Fischer, Luzern; Olivier Bonny, Lausanne*

OC 01

**Dietary intake of phosphate stimulates renal salt absorption and increases blood pressure (NCCR Project)**

**Arezoo Daryadel**<sup>1</sup>, Nilufar Mohebbi<sup>2</sup>, Udo Schnitzbauer<sup>3</sup>, Nicole Gehring<sup>1</sup>, Michael Föller<sup>4</sup>, Florian Lang<sup>4</sup>, Johannes Loffing<sup>5</sup>, Carsten Wagner<sup>3</sup>

<sup>1</sup>Institute of Physiology, University of Zurich, Zurich; <sup>2</sup>Division of Nephrology, University Hospital Zurich, Zurich; <sup>3</sup>Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich; <sup>4</sup>Institute of Physiology, University of Tübingen, Germany; <sup>5</sup>Institute of Anatomy, University of Zurich, Zurich

OC 02

**Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers compared to Conventional Dialysis in Patients with Cast Nephropathy**

**Adriano Curti**<sup>1</sup>, Albin Schwarz<sup>1</sup>, Yuki Tomonaga<sup>2</sup>, Patrice Ambühl<sup>1</sup>

<sup>1</sup>Institut für Nephrologie, Stadtspital Waid, Zürich; <sup>2</sup>Institut für Sozial- und Präventivmedizin, Universität Zürich, Zürich

OC 03

**Long-term impact of cardio-renal involvement on adverse outcomes in patients with Fabry disease**

Martin Siegenthaler<sup>1</sup>, Uyen Huynh-Do<sup>2</sup>, Urs Widmer<sup>3</sup>, Edouard Battegay<sup>1</sup>, Pierre-Alexandre Kraysenbühl<sup>4</sup>, **Albina Nowak**<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, University Hospital Zürich, Zürich; <sup>2</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern; <sup>3</sup>Swiss Reinsurance Company, Zürich; <sup>4</sup>Department of Internal Medicine, Kantonsspital Uznach, Uznach

OC 04

**Survival After Acute Kidney Injury in Patients with Acute Dyspnea**

**Tobias Breidthardt**, Raphael Twerenbold, Zaid Sabti, Max Wagener, Christian Puelacher, Stefan Osswald, Christian Müller  
Internal Medicine, University Hospital Basel, Basel

## Oral communications

**OC 05**      **Specialised renal care in patients with CKD stage IIIb-IV: does it impact on mortality and RRT implementation?**  
**Patrick Saudan**, Nicola Marangon, Chantal Martinez, Lena Berchtold, Thomas Hernandez, Sophie de Seigneux, Pierre-Yves Martin  
Nephrology Department, University Hospital of Geneva, Geneva

**OC 06**      **FGF23 and markers of mineral metabolism in subjects with preserved renal function**  
**Nasser Dhayat<sup>1</sup>**, Daniel Ackermann<sup>1</sup>, Menno Pruijm<sup>2</sup>, Belen Ponte<sup>3</sup>, Georg Ehret<sup>4</sup>, Idris Guessous<sup>5</sup>, Alexander Benedikt Leichtle<sup>6</sup>, Fred Paccaud<sup>7</sup>, Markus Mohaupt<sup>1</sup>, Georg-Martin Fiedler<sup>8</sup>, Michel Burnier<sup>2</sup>, Antoinette Pechère-Bertschi<sup>3</sup>, Pierre-Yves Martin<sup>3</sup>, Murielle Bochud<sup>7</sup>, Bruno Vogt<sup>1</sup>, Daniel Fuster<sup>9</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Bern; <sup>2</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>3</sup>Service of Endocrinology, Department of Specialties of Internal Medicine, University Hospital of Geneva (HUG), Geneva; <sup>4</sup>Cardiology, Department of Specialties of Internal Medicine, University Hospital of Geneva (HUG), Geneva; <sup>5</sup>University Hospitals of Geneva (HUG), Department of Community Medicine, Primary Care and Emergency Medicine and University Hospital of Lausanne (CHUV), Institute of Social and Preventive Medicine (IUMSP), Lausanne; <sup>6</sup>Center of Laboratory Medicine, Inselspital, Bern University Hospital and University of Bern, Bern; <sup>7</sup>University Hospital of Lausanne (CHUV), Institute of Social and Preventive Medicine (IUMSP), Lausanne; <sup>8</sup>Center of Laboratory Medicine, Inselspital, Bern University Hospital and University of Bern, Bern; <sup>9</sup>Division of Nephrology, Hypertension and Clinical Pharmacology, Department of Clinical Research, Institute of Biochemistry and Molecular Medicine and NCCR Kidney.ch, University of Bern, Bern



## Oral communications

### Oral Parallel Presentations

11.30 – 12.45 **Oral Parallel Presentations Basic Science** **Room B-Sydney**

*Chairs: Daniel Fuster, Bern; Olivier Devuyst, Zürich*

- OC 07** **An in vitro model of idiopathic membranous nephropathy reveals PLA2R- and complement-dependent pathways of podocyte injury**  
**George Haddad<sup>1</sup>**, Rudolf P. Wüthrich<sup>2</sup>, Andreas Kistler<sup>3</sup>  
<sup>1</sup>Institute of Physiology, University of Zurich, Zurich; <sup>2</sup>Division of Nephrology, University Hospital, Zurich; <sup>3</sup>Department of Internal Medicine, Nephrology unit, Cantonal Hospital Frauenfeld, Frauenfeld
- OC 08** **MEMO1 Deletion Impairs Renal FGF23 Signaling in vivo (NCCR project)**  
**Matthias Moor<sup>1</sup>**, Finola Legrand<sup>1</sup>, Barbara Hänzi<sup>2</sup>, Nancy Hynes<sup>3</sup>, Olivier Bonny<sup>4</sup>  
<sup>1</sup>Department of Pharmacology and Toxicology, University of Lausanne, Lausanne; <sup>2</sup>Wolfson Centre for Age Related Diseases, King's College London, London, UK; <sup>3</sup>Friedrich Miescher Institute for Biomedical Research, Basel; <sup>4</sup>Department of Pharmacology and Toxicology, University of Lausanne, Lausanne and Service of Nephrology, Lausanne University Hospital, Lausanne
- OC 09** **Higher serum galactose-deficient IgA1 level is associated with stronger mesangial inflammatory response and more severe histologic findings in IgA nephropathy**  
**Céline Nguyen<sup>1</sup>**, Frederick W K Tam<sup>2</sup>, Katrin König<sup>3</sup>, Helmut Hopfer<sup>4</sup>, Karen Molyneux<sup>5</sup>, Min Jeong Kim<sup>3</sup>  
<sup>1</sup>Department of Biomedicine, Molecular Nephrology, University Hospital Basel, Basel; <sup>2</sup>Renal & Transplant Centre, Hammersmith Hospital, Imperial College London, London, UK; <sup>3</sup>Clinic for Transplant Immunology and Nephrology, University Hospital Basel, Basel; <sup>4</sup>Institute for Pathology, University Hospital Basel, Basel; <sup>5</sup>Department of Infection, Immunity & Inflammation, University of Leicester, Leicester, UK
- OC 10** **Characterization of renal erythropoietin producing cells in vivo (NCCR Project)**  
**Karen Nolan<sup>1</sup>**, Faik Imeri<sup>1</sup>, Svende Pfundstein<sup>2</sup>, Sara Santambrogio<sup>2</sup>, Irene Abreu-Rodríguez<sup>2</sup>, Patrick Spielmann<sup>2</sup>, Carsten Scholz<sup>2</sup>, Edith

## Oral communications

Ummler<sup>3</sup>, Dominique Loffing-Cueni<sup>4</sup>, Johannes Loffing<sup>4</sup>,  
David Hoogewijs<sup>2</sup>, Roland Wenger<sup>2</sup>

<sup>1</sup>University of Zurich, Zurich; <sup>2</sup>Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich; <sup>3</sup>Transgenic Animal Facility (TAF), University of Lausanne, Lausanne; <sup>4</sup>Institute of Anatomy, University of Zurich, Zurich

OC 11

**Paraneoplastic nephrotic syndrome in small cell lung cancer is closely related to the induction of c-mip in podocytes via a circulating factor**

**Yassine Bouatou<sup>1</sup>**, Thibaud Kossler<sup>2</sup>, Shao-Yu Zhang<sup>3</sup>, Julie Oniszczuk<sup>3</sup>,  
Mélanie Mangier<sup>3</sup>, Solange Moll<sup>4</sup>, Jean-Claude Pache<sup>4</sup>, Nicolas Mach<sup>5</sup>,  
Vincent Audard<sup>6</sup>, Pierre-Yves Martin<sup>1</sup>, Djillali Sahali<sup>3</sup>, Sophie de Seigneux<sup>1</sup>

<sup>1</sup>Division of Nephrology, University Hospital of Geneva, Geneva; <sup>2</sup>Division of Oncology, Geneva University Hospitals, Geneva; <sup>3</sup>Inserm U955, équipe 21 IMRB - Institut Mondor de Recherche Biomédicale, Créteil- France;


<sup>4</sup>Division of Pathology, Geneva University Hospitals, Geneva; <sup>5</sup>Division of Oncology, Geneva University Hospitals, Geneva; <sup>6</sup>Service de Néphrologie et Transplantation, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Hôpital Henri-Mondor, Créteil - France

OC 12

**Mutation in the monocarboxylate acid transporter 12 gene affects guanidinoacetate excretion but does not cause glucosuria**

**Nasser Dhayat<sup>1</sup>**, Alexandre Simonin<sup>2</sup>, Manuel Anderegg<sup>1</sup>, Ganesh Pathare<sup>1</sup>, Benjamin Lüscher<sup>3</sup>, Christine Deisl<sup>1</sup>, Giuseppe Albano<sup>1</sup>, David Mordasini<sup>1</sup>, Matthias Hediger<sup>1</sup>, Daniel Surbek<sup>3</sup>, Bruno Vogt<sup>1</sup>, Jörn Oliver Sass<sup>4</sup>, Barbara Kloeckener-Gruissem<sup>5</sup>, Daniel Fuster<sup>1</sup>

<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Bern; <sup>2</sup>Institute of Biochemistry and Molecular Medicine and NCCR Transcure, University of Bern, Bern; <sup>3</sup>Department of Obstetrics and Gynecology, Department of Clinical Research and Institute of Biochemistry and Molecular Medicine and NCCR Transcure, University of Bern, Bern; <sup>4</sup>Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, Rheinbach, Germany and Division of Clinical Chemistry & Biochemistry and Children's Research Center, University Children's Hospital, Zürich; <sup>5</sup>Institute of Medical Molecular Genetics, University of Zürich and Department of Biology, Swiss Federal Institute of Technology in Zürich, Zürich



# Novel insight into the clinical management of ADPKD

An Otsuka-sponsored  
symposium

Thursday, 3<sup>rd</sup> December 2015  
13:00 – 13:45

SGN-SSN 2015,  
Congress Center Basel, Room A

## PROGRAMME AND SPEAKERS:

### Welcome & Introduction

*Prof. Dr. Rudolf Wüthrich,  
University Hospital Zurich*

### ADPKD – The course of the disease and factors for disease progression


*Prof. Dr. Pierre-Yves Martin,  
University Hospital Geneva*

### Emerging treatment options in ADPKD

*Prof. Dr. Peter Gross, University  
Hospital Carl Gustav Carus, Dresden*

*Q&A session moderated by  
Prof. Dr. Rudolf Wüthrich*

# GET CONNECTED TO PATIENTS ON HOME DIALYSIS



## Lunch Symposium

### IMPROVING HOME DIALYSIS OUTCOMES THROUGH REMOTE MONITORING

Thursday, December 3, 2015

13:00 – 13:45

Congress Center Basel, Room B

Speaker: **Prof. Dr. Manuel Pestana**, Porto

Chair: **Prof. Dr. Stephan Segerer**, Zürich

**Baxter**

# Thursday, December 3

13.00-13.45

Satellite Lunch Symposia

Room A-Singapore

Sponsored by OTSUKA



**Novel insight into the clinical management of ADPKD**

– **Welcome & Introduction**

Rudolf Wüthrich, Zurich

– **ADPKD – The course of the disease and factors for disease progression**

Pierre-Yves Martin, Genève

– **Emerging treatment options in ADPKD**

Peter Gross, Dresden (DE)

– **Q&A session moderated by**

Rudolf Wüthrich, Zurich

Sponsored by BAXTER

**Baxter** Room B-Sydney

**Improving Home Dialysis Outcomes through Remote Monitoring**

*Chair: Stephan Segerer, Zurich*

*Speaker: Manuel Pestana, Porto (PT)*

13.45-14.30

Standing Lunch at the Exhibition

Exhibition space

14.30-15.30

**Posterwalk**

Poster area

Olivier Devuyst, Zürich; Daniel Fuster, Bern;

Olivier Bonny, Lausanne; Michael Dickenmann, Basel;

Stefan Farese, Solothurn; Patrizia Amico, Basel

15.30-16.00

Coffee Break – Visit of the Exhibition

Exhibition space

## Novartis Satellite Symposium


3<sup>rd</sup> December 2015, 17:15–18:15, Room A

# Key Role of Nephrologists in Tuberous Sclerosis Management with a Systemic Treatment

Prof. O. Bonny, Lausanne (Chair)

Dr. F. Fellmann, Lausanne

Dr. P. Dill, Basel



[www.facingtsc.com](http://www.facingtsc.com)



# Thursday, December 3

16.00-17.00 Parallel Symposia

16.00-17.00 **Symposium Clinical Nephrology** **Room A-Singapore**  
*Chairs: Min-Jeong Kim, Basel; Luca Gabutti, Locarno*

16.00-16.30 **How to slow progression of CKD**  
Andreas Kistler, Frauenfeld

16.30-17.00 **Current and future treatments for ADPKD**  
Rudolf Wüthrich, Zürich


16.00-17.00 **Symposium NCCR / Basic Science** **Room B-Sydney**  
*Chairs: Pierre-Yves Martin, Geneva; Olivier Devuyst, Zürich*

16.00-16.20 **Sensing and control of acid-base balance**  
Carsten Wagner, Zürich

16.20-16.40 **Fetuin A: new views on an old molecule**  
Uyen Huynh-Do, Bern

16.40-17.00 **NEDD4-2 and blood pressure regulation**  
Olivier Staub, Lausanne

17.00-17.15 Short break Exhibition space


17.15-18.15 **Satellite Symposium** **Room A-Singapore**  
Sponsored by NOVARTIS  
**Key Role of Nephrologists in Tuberos Sclerosis Management with a Systemic Treatment**   
*Chair: Olivier Bonny, Lausanne*  
Speakers: Florence Fellmann, Lausanne; Patricia Dill, Basel

19.30 **Poster Prize Awards**  
Sponsored by ROCHE



**Room B-Sydney**

**& CONGRESS DINNER**



**Individualized Therapy**  
because every patient is different

## **Satellite Symposium**

### **HD MEMBRANES – CHOICES FOR INDIVIDUALIZED CARE**

Friday, December 4, 2015

12:00 – 12:45

Congress Center Basel, Room A

Speaker: **Prof. Dr. Alexander Rosenkranz**, Graz

Chair: **Dr. Menno Pruijm**, Lausanne

Baxter AG, Müllerenstrasse 3, CH-8604 Volketswil

**Baxter**

Making possible personal.



# Friday, December 4

From 07.00	Registration	
08.00-09.30	<b>GENERAL ASSEMBLY SGN-SSN</b>	<b>Room A-Singapore</b>
09.30-10.00	<b>The Swiss Dialysis Registry</b> Patrice Ambühl, Zürich <i>Chair: Jürg Steiger, Basel</i>	<b>Room A-Singapore</b>
10.00-10.30	Coffee Break – Visit of the Exhibition	Exhibition space
10.30-10.45	<b>SGN-SSN Publication Award 2015</b> <i>Chair: Jürg Steiger, Basel</i>  Presentation and short address Sophie de Seigneux, Geneva <b><i>Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling</i></b>	
10.45-11.45	<b>State of the Art Lectures</b> <i>Chairs: Andreas Bock, Aarau ; Thomas Neuhaus, Luzern</i>	<b>Room A-Singapore</b>
10.45-11.15	<b>HLA matching: past, present and future (Gil Thiel lecture)</b> Frans Claas, Leiden (NL)	
11.15-11.45	<b>Who needs long-term steroids in kidney transplantation?</b> Thomas Müller, Zürich	
11.45-12.00	Break	
12.00-12.45	<b>Satellite Symposia</b> Sponsored by BAXTER  <b>HD Membranes, Choices for Individualised Care</b> <i>Chair: Menno Prujim, Lausanne</i> Speaker: Alexander Rosenkranz, Graz (AT)	<b>Room A-Singapore</b>
12.00-12.45	<b>Satellite Symposia</b> Sponsored by VIFOR  <b>Vifor Pharma</b> <b>Management of hyperphosphatemia in dialysis patients: from bench to bedside</b> 1. <b>Vitamin D, Calcium and Phosphate, an important triad in CKD patients</b> Markus Ketteler, Coburg (DE) 2. <b>A Swiss Nephrologist's snapshot of the new Ca<sup>2+</sup>-free phosphate binder</b> Olivier Phan, Lausanne	<b>Room B-Sydney</b>
12.45-13.00	Break	

# MANAGEMENT OF HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS

Chairman:  
Prof. Markus  
Ketteler

From bench to bedside

Friday, December 4, 2015, 12.00 – 12.45 h

Room B, Congress Center Basel

**Vitamin D, Calcium and Phosphate,  
an important triad in CKD patients**

**Prof. Markus Ketteler**, Coburg Clinic and KfH-  
Dialysis Center, Coburg, Germany

**A Swiss Nephrologist's snapshot of  
the new Ca<sup>2+</sup>-free phosphate binder**

**Dr. Olivier Phan**, CHUV, Lausanne, Switzerland

# Speakers / Moderators

Ambühl Patrice, [Zurich](#)

Amico Patrizia, [Basel](#)

Binet Isabelle, [St. Gallen](#)

Bock Andreas, [Aarau](#)

Bonny Olivier, [Lausanne](#)

Burkhalter Felix, [Basel](#)

Burnier Michel, [Lausanne](#)

Claas Frans, [Leiden \(NL\)](#)

Claes Veerle, [Basel](#)

De Geest Sabina, [Basel](#)

Devuyt Olivier, [Zurich](#)

Dickenmann Michael, [Basel](#)

Farese Stefan, [Solothurn](#)

Fischer Andreas, [Lucerne](#)

Fuster Daniel, [Bern](#)

Gabutti Luca, [Locarno](#)

Hils Silvia, [Freiburg \(DE\)](#)

Hirt-Minkowski Patricia, [Basel](#)

Hopfer Helmut, [Basel](#)

Huynh-Do Uyen, [Bern](#)

Kim Min-Jeong, [Basel](#)

Kistler Andreas, [Frauenfeld](#)

Martin Pierre-Yves, [Geneva](#)

Mauthner Oliver, [Basel](#)

Meyer-Schwesinger Catherine, [Hamburg \(DE\)](#)

Moll Solange, [Geneva](#)

Müller Thomas, [Zurich](#)

Neuhaus Thomas, [Lucerne](#)

Schaub Stefan, [Basel](#)

Schmid-Mohler Gabriela, [Zurich](#)

Staub Olivier, [Lausanne](#)

Steiger Jürg, [Basel](#)

Tharaux Pierre-Louis, [Paris \(FR\)](#)

Venzin Reto, [Chur](#)

Vogt Bruno, [Bern](#)

Wagner Carsten, [Zurich](#)

Wilson Patrick, [Delémont](#)

Wolff Thomas, [Basel](#)

Wüthrich Rudolf, [Zurich](#)

Zala Patrizia, [Zurich](#)

**AMGEN**<sup>®</sup>

invites you to a Scientific Symposium

## **Cardiovascular risk prevention in CKD patients: what can we do better?**

Friday December 4<sup>th</sup>, 2015  
from 1.00 pm – 1.45 pm

---

**Chair:**

Professor M. Burnier  
CHUV, Switzerland

**Speakers:**

**the heart perspective**

Professor Dr G. Noll  
HerzKlinik Hirslanden Zürich, Switzerland

**the kidney – vessels perspective**

Dr G. Würzner  
CHUV, Switzerland



**AMGEN**<sup>®</sup>

AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, [www.amgen.ch](http://www.amgen.ch)

# Friday, December 4

13.00-13.45

Satellite Lunch Symposia

Room A-Singapore

Sponsored by AMGEN



**Cardiovascular risk prevention in CKD patients:  
what can we do better?**

*Chair: Michel Burnier, Lausanne*

– **The heart perspective**

Georg Noll, Zurich

– **The kidney – vessels perspective**

Grégoire Würzner, Lausanne

Sponsored by ASTELLAS



Room B-Sydney

**Registry real-world data and  
long-term graft survival in kidney transplantation**

Dorry Segev, Baltimore (USA)

Jürg Steiger, Basel

Déla Golshayan, Lausanne

13.45-14.30

Standing Lunch at the Exhibition – Poster Viewing

Exhibition space

14.30-15.45

Oral Parallel Presentations

14.30-15.45

**Hemodialysis and PD**

Room A-Singapore

*Chairs: Patrick Wilson, Delémont; Reto Venzin, Chur*

6 oral presentations

14.30-15.45

**Transplantation**

Room B-Sydney

*Chairs: Patrizia Amico, Basel; Isabelle Binet, St.Gallen*

6 oral presentations

15.45-16.15

Coffee Break – Visit of the Exhibition

Exhibition space

LUNCH PARALLEL SYMPOSIUM

# Registry real-world data and long-term graft survival in kidney transplantation

Friday, 4th December 2015, 13.00–13.45 h

Kongresssaal, Congress Center Basel

47th Annual Meeting of the Swiss Society of Nephrology



Scan the QR code with your smart phone to enter this meeting directly into your calendar.

APCHADMIN0815e

# Oral communications

## Oral Parallel Presentations

14.30-15.45

**Hemodialysis and PD**

**Room A-Singapore**

*Chairs: Patrick Wilson, Delémont; Reto Venzin, Chur*

OC 13

**Overhydration is a strong predictor of mortality independently of cardiac failure in peritoneal dialysis patients**

**Valérie Jotterand Drepper<sup>1</sup>**, Lars Kihm<sup>2</sup>, Christian Diekmann<sup>2</sup>, Jörg Seckinger<sup>2</sup>, Claudia Sommerer<sup>2</sup>, Martin Zeier<sup>2</sup>, Vedat Schwenger<sup>3</sup>  
<sup>1</sup>Division of Nephrology, University Hospital, Geneva, Geneva; <sup>2</sup>University Hospital Heidelberg, Heidelberg, Germany; <sup>3</sup>Katharinenhospital, Stuttgart, Germany

OC 14

**Study of the possible physiological effects of antioxidants on some markers of neutrophil activation in chronic hemodialysis patients**

**Maha Deif<sup>1</sup>**, Howaida Nounou<sup>2</sup>, Wafaa Abd El Dayem<sup>1</sup>, Iman Al Gohary<sup>1</sup>

<sup>1</sup>Alexandria University, Alexandria, Egypt; <sup>2</sup>King Saud University, Riyadh, Kingdom of Saudi Arabia

OC 15

**Preliminary results of dialysis study: accuracy of a single pool variable-volume calcium kinetic model with different calcium dialysate concentrations**

Salvatore Di Filippo<sup>1</sup>, **Vincenzo La Milia<sup>1</sup>**, Fabio Carfagna<sup>1</sup>, Claudio Minoretto<sup>2</sup>, Giuseppe Rombolà<sup>3</sup>, Carlo Schönholzer<sup>4</sup>, Giustina Casagrande<sup>5</sup>, Camilla Bianchi<sup>5</sup>, Maria Laura Costantino<sup>5</sup>, Giuseppe Pontorero<sup>6</sup>, Francesco Locatelli<sup>1</sup>

<sup>1</sup>Nephrology and Dialysis, A.O. Lecco, Lecco, Italy; <sup>2</sup>Nephrology and Dialysis, A.O. Sant'Anna, Como, Italy; <sup>3</sup>Nephrology and Dialysis, Ospedale di Circolo e Fondazione Macchi, Varese, Italy; <sup>4</sup>Regional Hospital of Lugano, Lugano; <sup>5</sup>Politecnico di Milano, Milano, Italy; <sup>6</sup>Alessandro Manzoni Hospital, Lecco, Italy

OC 16

**Benefits of Transonic® access flow measurement and percutaneous angioplasty**

**Christoph Lenherr<sup>1</sup>**, Damien Toja<sup>2</sup>, Denes Kiss<sup>1</sup>

<sup>1</sup>Division of Nephrology, Kantonsspital Baselland, Liestal; <sup>2</sup>Division of Radiology, Kantonsspital Baselland, Liestal

## Oral communications

OC 17

### A new method to personalize dialysis therapy

**Camilla Bianchi**<sup>1</sup>, Giustina Casagrande<sup>1</sup>, Giuseppe Pontoriero<sup>2</sup>, Carlo Schönholzer<sup>3</sup>, Maria Laura Costantino<sup>1</sup>

<sup>1</sup>Politecnico di Milano, Milano, Italy; <sup>2</sup>Alessandro Manzoni Hospital, Lecco, Italy; <sup>3</sup>Regional Hospital of Lugano, Lugano

OC 18

### Changing trends in end-stage renal disease patients with diabetes in the canton of Vaud between 2009 and 2014

**Yimin Lu**<sup>1</sup>, Christina Stamm<sup>1</sup>, Dina Duarte-vaquinhas-nobre<sup>1</sup>, Menno Pruijm<sup>1</sup>, Daniel Teta<sup>1</sup>, Anne Cherpillod<sup>2</sup>, Georges Halabi<sup>3</sup>, Olivier Phan<sup>4</sup>, Zina Fumeaux<sup>5</sup>, Roberto Bullani<sup>6</sup>, Thierry Gauthier<sup>7</sup>, Claudine Mathieu<sup>2</sup>, Michel Burnier<sup>1</sup>, Anne Zanchi<sup>1</sup>

<sup>1</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>2</sup>Hemodialysis Unit, Cecil Clinic, Lausanne; <sup>3</sup>Hemodialysis Unit, Northern Vaud Hospital, Yverdon; <sup>4</sup>Hemodialysis Unit, Broye Intercantonal Hospital, Payerne; <sup>5</sup>Hemodialysis Unit, Nyon Hospital, Nyon; <sup>6</sup>Hemodialysis Unit, EHC Hospital, Morges; <sup>7</sup>Hemodialysis Unit, Riviera Providence Hospital, Vevey



## Oral communications

### Oral Parallel Presentations

14.30-15.45

Transplantation

Room B-Sydney

*Chairs: Patrizia Amico, Basel; Isabelle Binet, St.Gallen*

OC 19

**Influence of hip position on oxygenation and perfusion of renal transplants: The bent knee study- a pilot study**

**Laila-Yasmin Mani**<sup>1</sup>, Maryam Seif<sup>2</sup>, Bruno Vogt<sup>1</sup>, Peter Vermathen<sup>2</sup>

<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University of Bern, Bern; <sup>2</sup>Dept. Clinical Research and Radiology, University of Bern, Bern

OC 20

**Belatacept-treated patients had superior graft survival compared with cyclosporine-treated patients: final results from BENEFIT**

**Flavio Vincenti**<sup>1</sup>, Robert Bray<sup>2</sup>, Howard Gebel<sup>2</sup>, Josep Grinyó<sup>3</sup>, Marie-Christine Moal<sup>4</sup>, Kim Rice<sup>5</sup>, Lionel Rostaing<sup>6</sup>, Steven Steinberg<sup>7</sup>, Ulf Meier-Kriesche<sup>8</sup>, Martin Polinsky<sup>8</sup>, Robert Townsend<sup>8</sup>, Christian P Larsen<sup>2</sup>

<sup>1</sup>University of California, San Francisco, USA; <sup>2</sup>Emory University, Atlanta, Georgia, USA; <sup>3</sup>University Hospital Bellvitge, Barcelona, Spain; <sup>4</sup>Hôpital de La Cavale Blanche, Brest, France; <sup>5</sup>Baylor University Medical Center, Dallas, Texas, USA; <sup>6</sup>University Hospital, and INSERM U563, IFR-BMT, Toulouse, France; <sup>7</sup>Sharp Memorial Hospital, San Diego, California, USA; <sup>8</sup>Bristol-Myers Squibb, USA

OC 21

**Chronic transplant vasculopathy in renal allografts: a result of undiagnosed rejection and suboptimal treatment strategies**

**Argyrios Georgalis**<sup>1</sup>, Caroline Wehmeier<sup>1</sup>, Patricia Hirt-Minkowski<sup>1</sup>, Gideon Hönger<sup>1</sup>, Helmut Hopfer<sup>2</sup>, Jürg Steiger<sup>1</sup>, Stefan Schaub<sup>1</sup>, Patrizia Amico<sup>1</sup>

<sup>1</sup>Department of Transplantation Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Institute for Pathology, University Hospital Basel, Basel

## Oral communications

- OC 22**      **2222 kidney transplantations at the University Hospital Basel: a story of success and new challenges**  
**Caroline Wehmeier<sup>1</sup>**, Argyrios Georgalis<sup>1</sup>, Patricia Hirt-Minkowski<sup>1</sup>, Patrizia Amico<sup>1</sup>, Gideon Hönger<sup>1</sup>, Thomas Vögele<sup>1</sup>, Nicole Brun<sup>1</sup>, Andreas Bock<sup>2</sup>, Lorenz Gürke<sup>3</sup>, Alexander Bachmann<sup>4</sup>, Helmut Hopfer<sup>5</sup>, Michael Dickenmann<sup>1</sup>, Jür Steiger<sup>1</sup>, Stefan Schaub<sup>1</sup>  
<sup>1</sup>Department of Transplantation Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Department of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau; <sup>3</sup>Department of Vascular and Transplant Surgery, University Hospital Basel, Basel; <sup>4</sup>Department of Urology, Basel University Hospital, Basel; <sup>5</sup>Institute for Pathology, University Hospital Basel, Basel
- OC 23**      **Six-month urinary CCL2 and CXCL10 levels predict long-term renal allograft outcome**  
**Patricia Hirt-Minkowski<sup>1</sup>**, David N. Rush<sup>2</sup>, Ang Gao<sup>3</sup>, Helmut Hopfer<sup>4</sup>, Chris Wiebe<sup>2</sup>, Peter Nickerson<sup>2</sup>, Stefan Schaub<sup>1</sup>, Julie Ho<sup>2</sup>  
<sup>1</sup>Transplantationsimmunology & Nephrology, University Hospital Basel, Basel; <sup>2</sup>Section of Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada; <sup>3</sup>Manitoba Centre for Proteomics and Systems Biology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; <sup>4</sup>Institute for Pathology, University Hospital Basel, Basel
- OC 24**      **The kSORT assay in kidney transplant recipients: first experience in Switzerland**  
**Yassine Bouatou<sup>1</sup>**, Sue Hsieh<sup>2</sup>, Christine Deffert<sup>3</sup>, Pierre-Yves Martin<sup>1</sup>, Thierry Berney<sup>4</sup>, Minnie Sarwal<sup>2</sup>, Karine Hadaya<sup>1</sup>  
<sup>1</sup>Divisions of Nephrology and Transplantation, Geneva University Hospitals, Geneva; <sup>2</sup>Department of Surgery, University of California San Francisco, San Francisco, California, USA; <sup>3</sup>Department of Pathology and Immunology, Geneva University Hospitals, Geneva; <sup>4</sup>Division of Transplantation, Geneva University Hospitals, Geneva

# Friday, December 4

16.15-17.15	<b>The four best studies of the last year !</b> <i>Chairs: Bruno Vogt, Bern; Michel Burnier, Lausanne</i>	<b>Room A-Singapore</b>
16.15-16.30	<b>Basic science</b> Olivier Devuyst, Zürich	
16.30-16.45	<b>Clinical Nephrology</b> Min-Jeong Kim, Basel	
16.45-17.00	<b>HD / PD</b> Stefan Farese, Solothurn	
17.00-17.15	<b>Transplantation</b> Patricia Hirt-Minkowski, Basel	
17.15	<b>Farewell</b> Jürg Steiger, Basel	

# Poster presentations

## Clinical Nephrology / Hypertension / Mineral / Electrolytes

- P 01**                    **Probability of Renal Stone Formation in obese patients before gastric bypass surgery**  
**Thomas Hernandez**<sup>1</sup>, Catherine Stoermann Chopard<sup>1</sup>, Minoa Jung<sup>2</sup>, Pierre-Yves Martin<sup>1</sup>, Philippe Jaeger<sup>1</sup>  
<sup>1</sup>Service of Nephrology, University Hospital of Geneva, Geneva; <sup>2</sup>Service of Visceral Surgery, University Hospital of Geneva, Geneva
- P 02**                    **Parathyroid hormone is critical for the acute adaption to oral or intravenous phosphate loading (NCCR Project)**  
**Linto Thomas**, Carla Bettoni, Udo Schnitzbauer, Jürg Biber, Nati Hernando, Carsten Wagner  
Institute of Physiology, Zurich; Centre for Integrative Human Physiology, University of Zurich, Zurich
- P 03**                    **Outcome of "double positive" anti GBM disease: A case report**  
**Dirk Bareiss**<sup>1</sup>, Thomas Menter<sup>2</sup>, Helmut Hopfer<sup>2</sup>, Andreas Jehle<sup>1</sup>, Felix Burkhalter<sup>1</sup>  
<sup>1</sup>Clinic for Transplant Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Institute for Pathology, University Hospital Basel, Basel
- P 04**                    **Community-acquired enterococcal urinary tract infection**  
**Emine Gashaj**<sup>1</sup>, Alex Donas<sup>1</sup>, Thomas Neuhaus<sup>1</sup>, Michael Büttcher<sup>2</sup>  
<sup>1</sup>Pädiatrische Klinik, Kinderspital Luzern, Luzern, <sup>2</sup>Klinik für Kinder und Jugendliche, Stadtspital Triemli Zürich, Zürich
- P 05**                    **Nephrologic psychiatry: hyponatremia in a depressive woman – a case report**  
**Peter Kern**, Tobias Öttl, Susanne Christen  
Gesundheitszentrum (GZF), Rheinfelden
- P 06**                    **Nephrogenic Diabetes insipidus due to Sevoflurane administration**  
**Ineke Grendelmeier**<sup>1</sup>, Annekathrin Mehlig<sup>2</sup>, Denes Kiss<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Kantonsspital Baselland, Liestal; <sup>2</sup>Division of Intensive Care Medicine, Kantonsspital Baselland, Liestal

## Poster presentations

- P 07**                    **Neolymphangiogenesis is related to worse clinical outcome in lupus nephritis**  
**Suzan Dahdal**, Dominik Uehlinger, Uyen Huynh-Do  
Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital and University of Bern, Inselspital, Bern
- P 08**                    **Contrast-enhanced Ultrasound (CEUS) of the kidney – a prospective evaluation of its value in the detection and risk stratification of pyelonephritis**  
**Florian Buchkremer**<sup>1</sup>, Daniel Drozdov<sup>2</sup>, Werner Albrich<sup>3</sup>, Andreas Bock<sup>1</sup>  
<sup>1</sup>Department of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau; <sup>2</sup>Medical University Department, Kantonsspital Aarau, Aarau; <sup>3</sup>Department of Infectious Diseases, Kantonsspital St. Gallen, St. Gallen
- P 09**                    **Postpartum anuric renal failure in a Jehovah's witness with catastrophic antiphospholipid syndrome**  
Andreas Fischer<sup>1</sup>, **Emily Pollock**<sup>1</sup>, Andreas Bosshard<sup>2</sup>, Janine Schmid<sup>2</sup>, Joachim Kohl<sup>3</sup>, Walter Wuillemin<sup>4</sup>  
<sup>1</sup>Division of Nephrology, Cantonal Hospital of Lucerne, Luzern; <sup>2</sup>Intensive Care Center, Cantonal Hospital of Lucerne, Luzern; <sup>3</sup>Department of Gynecology and Obstetrics, Cantonal Hospital of Lucerne, Luzern; <sup>4</sup>Division of Hematology and Central Laboratory of Hematology, Cantonal Hospital of Lucerne, Luzern
- P 10**                    **Long-term renal outcome in lithium-treated patients: experience of a single swiss centre**  
**Martin Scoglio**<sup>1</sup>, Curzio Solca<sup>1</sup>, Luigi Cornalba<sup>1</sup>, Alberto Foglia<sup>2</sup>, Claudia Ferrier<sup>1</sup>  
<sup>1</sup>Clinica Luganese e Centro Dialisi Dr.ssa Ferrier, Lugano; <sup>2</sup>Psychiatric outpatient Clinic, studio Dr. A. Foglia, Lugano
- P 11**                    **Wunderlich syndrome in a chronic kidney disease patient on hemodialysis: a case report**  
Annabel Yap<sup>1</sup>, **Patricia dela Rosa**<sup>1</sup>  
<sup>1</sup>Department of Internal Medicine, Delos Santos Medical Center, Quezon City, Philippines

## Poster presentations

- P 12**      **Effect of Enzyme Replacement Therapy on Fabry Nephropathy Progression**  
**Albina Nowak**<sup>1</sup>, Gilbert Koch<sup>2</sup>, Uyen Huynh-Do<sup>3</sup>, Martin Siegenthaler<sup>1</sup>, Hans-Peter Marti<sup>4</sup>, Edouard Battegay<sup>1</sup>, Marc Pfister<sup>2</sup>  
<sup>1</sup>Department of Internal Medicine, University Hospital Zürich, Zürich; <sup>2</sup>Pediatric Clinical Pharmacology, University Children Hospital Basel, Basel; <sup>3</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern; <sup>4</sup>Department of Clinical Medicine, University of Bergen, Bergen, Norway
- P 13**      **Effect of acute hyperglycemia on renal tissue oxygenation as measured with BOLD-MRI in overweight individuals and persons with impaired glucose tolerance**  
**Nima Vakilzadeh**<sup>1</sup>, Bastien Milani<sup>1</sup>, Christiane Anex<sup>1</sup>, Matthias Stuber<sup>2</sup>, Anne Zanchi<sup>1</sup>, Michel Burnier<sup>1</sup>, Menno Pruijm<sup>1</sup>  
<sup>1</sup>Service of Nephrology and Hypertension, University Hospital Lausanne (CHUV), Lausanne; <sup>2</sup>Department of Radiology, University Hospital Lausanne (CHUV), Lausanne
- P 14**      **Metabolic acidosis stimulates calcium and magnesium excretion via OGR1**  
**Pedro Henrique Imenez Silva**<sup>1</sup>, Chahira Benabbas<sup>1</sup>, Kessara Chan<sup>1</sup>, Marie-Gabrielle Ludwig<sup>2</sup>, Jürg Gasser<sup>2</sup>, Timothy Arnett<sup>3</sup>, Olivier Bonny<sup>4</sup>, Klaus Seuwen<sup>2</sup>, Carsten Wagner<sup>1</sup>  
<sup>1</sup>Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich; <sup>2</sup>Novartis Institutes for BioMedical Research, Basel; <sup>3</sup>Department of Cell and Developmental Biology, University College, London, U.K.; <sup>4</sup>Department of Pharmacology and Toxicology, University of Lausanne, Lausanne
- P 15**      **Acute tubular necrosis- a rare side effect of dabigatran?**  
**Hanno Elsässer**<sup>1</sup>, Helmut Hopfer<sup>2</sup>, Denes Kiss<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Kantonsspital Baselland, Liestal; <sup>2</sup>Institute for Pathology, University Hospital Basel, Basel
- P 16**      **A case of Membranoproliferative Glomerulonephritis associated with Hypocomplementemic urticarial Vasculitis in Fribourg Switzerland**  
**Ould Maouloud Hemett**<sup>1</sup>, Descombes Eric<sup>1</sup>, Samuel Rotman<sup>2</sup>, Veronique Erard<sup>3</sup>, Vincent Morel<sup>3</sup>, Daniel Hayoz<sup>3</sup>

## Poster presentations

<sup>1</sup>Nephrology and Hemodialysis Unit, Hôpital Cantonal de Fribourg, Fribourg; <sup>2</sup>University Institute of Pathology, CHUV, Lausanne; <sup>3</sup>Internal Medicine, HFR, Hôpital Cantonal Fribourg, Fribourg

- P 17**      **Type 2 primary hyperoxaluria - an unusual cause of nephrolithiasis and renal failure**  
**Florian Buchkremer**, Bojan Bicanski, Andreas Bock  
Department of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau
- P 18**      **A case of unusual discoloration of urine**  
**Catherine Stoermann Chopard**, Thomas Hernandez, Pierre-Yves Martin  
Service of Nephrology, University Hospital of Geneva, Geneva
- P 19**      **Recurrent catastrophic antiphospholipid syndrome treated with eculizumab in a peritoneal dialysis patient**  
Silvio Pianca<sup>1</sup>, Marianna De Francesco<sup>1</sup>, Lisa Pellegrini<sup>1</sup>, Josua Van Den Berg<sup>2</sup>, **Carlo Schönholzer**<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>2</sup>Division of Interventional Radiology, Ospedale Regionale di Lugano, Lugano
- P 20**      **The V-ATPase B1 subunit polymorphism p.E161K is associated with impaired urinary acidification in recurrent stone formers**  
**Nasser Dhayat**<sup>1</sup>, André Schaller<sup>2</sup>, Giuseppe Albano<sup>1</sup>, John Poindexter<sup>3</sup>, Carolyn Griffith<sup>3</sup>, Andreas Pasch<sup>4</sup>, Sabina Gallati Kraemer<sup>2</sup>, Bruno Vogt<sup>1</sup>, Orson Moe<sup>3</sup>, Daniel Fuster<sup>4</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Bern; <sup>2</sup>Division of Human Genetics, Departments of Pediatrics and Clinical Research, Inselspital, Bern University Hospital and University of Bern, Bern; <sup>3</sup>Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texa, USA; <sup>4</sup>Division of Nephrology, Hypertension and Clinical Pharmacology, Department of Clinical Research, Institute of Biochemistry and Molecular Medicine and NCCR Kidney.ch, University of Bern, Bern
- P 21**      **Polyvinylpyrrolidone storage disease in a drug addicted patient - a lesson from Norway**  
Erik H. Strom<sup>1</sup>, Friedemann Leh<sup>2</sup>, Heidi Gronseth<sup>2</sup>, Sabine Leh<sup>2</sup>, **Helmut Hopfer**<sup>3</sup>

## Poster presentations

<sup>1</sup>Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; <sup>2</sup>Department of Pathology, Haukeland University Hospital, Bergen, Norway; <sup>3</sup>Institute for Pathology, University Hospital Basel, Basel

P 22

### Postpartal thrombotic microangiopathy – HELLP or HUS?

**Claudia Kobel**<sup>1</sup>, Patrice Ambühl<sup>1</sup>, Simone Brandt<sup>2</sup>, Patricia Fodor<sup>3</sup>, Christoph Etter<sup>1</sup>

<sup>1</sup>Institute of Nephrology and Dialysis, Stadtspital Waid, Zurich;

<sup>2</sup>Department of Surgical Pathology, University Hospital Zurich, Zurich;

<sup>3</sup>Institute of Anesthesiology, Stadtspital Triemli, Zurich

P 23

### Successful management of severe hypernatraemia, rhabdomyolysis and acute kidney injury (aki) with hyper-osmolar dialysate solutions in continuous renal replacement therapy (crrt)

**Marianna De Francesco**<sup>1</sup>, Marco Conti<sup>2</sup>, Davide Giunzioni<sup>1</sup>, Silvio Pianca<sup>1</sup>, Paolo Merlani<sup>2</sup>, Carlo Schönholzer<sup>1</sup>

<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>2</sup>Division of Intensive Care, Ospedale Regionale di Lugano, Lugano

P 24

### Uromodulin modulates the effect of salt on blood pressure in the general population

**Belen Ponte**<sup>1</sup>, Menno Pruijm<sup>2</sup>, Idris Guessous<sup>3</sup>, Daniel Ackermann<sup>4</sup>, Georg Ehret<sup>5</sup>, Markus Mohaupt<sup>4</sup>, Fred Paccaud<sup>6</sup>, Bruno Vogt<sup>4</sup>, Pierre-Yves Martin<sup>1</sup>, Antoinette Pechère-Bertschi<sup>7</sup>, Michel Burnier<sup>2</sup>, Olivier Devuyst<sup>8</sup>, Murielle Bochud<sup>6</sup>

<sup>1</sup>Department of Nephrology, University Hospital of Geneva, Geneva;

<sup>2</sup>Service of Nephrology and Hypertension, University Hospital of

Lausanne (CHUV), Lausanne; <sup>3</sup>Department of Community Medicine,

Primary Care and Emergency Medicine, University Hospitals of Geneva

(HUG) and Institute of Social and Preventive Medicine (IUMSP),

Emergency Medicine and University Hospital of Lausanne (CHUV),

Lausanne; <sup>4</sup>Department of Nephrology, Hypertension and Clinical

Pharmacology, University Hospital and University of Bern, Inselspital,

Bern; <sup>5</sup>Division of Cardiology, University Hospital of Geneva, Geneva;

<sup>6</sup>Institute of Social and Preventive Medicine (IUMSP), University

Hospital of Lausanne (CHUV), Lausanne; <sup>7</sup>Service of Endocrinology,

Department of Specialties of Internal Medicine, University Hospital

of Geneva (HUG), Geneva; <sup>8</sup>Institute of Physiology, Zurich Centre for

Integrative Human Physiology, University of Zurich, Zurich



## Poster presentations

- P 25**      **C-terminal fragment of agrin (CAF) predicts acute kidney injury and long term mortality after acute myocardial infarction – A cohort study**  
**Spyridon Arampatzis<sup>1</sup>**, Georgios Chalikias<sup>2</sup>, Vasileios Devetzi<sup>1</sup>, Stefan Hettwer<sup>3</sup>, Stavros Konstantinides<sup>2</sup>, Dimitrios Tziakas<sup>2</sup>, Uyen Huynh-Do<sup>1</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern; <sup>2</sup>Department of Cardiology, Medical School, Democritus University of Thrace, Alexandroupoli, Greece; <sup>3</sup>Neurotune AG, 8952 Schlieren/ZH
- P 26**      **C-terminal fragment of agrin (CAF) is associated with GFR and proteinuria and predicts progression of kidney disease in type 2 diabetics**  
**Spyridon Arampatzis<sup>1</sup>**, **Vasileios Devetzi<sup>1</sup>**, Stefanos Roumeliotis<sup>2</sup>, Marios Theodoridis<sup>2</sup>, Stefan Hettwer<sup>3</sup>, Athanasios Roumeliotis<sup>2</sup>, Stelios Panagoutsos<sup>2</sup>, Ploumis Passadakis<sup>2</sup>, Uyen Huynh-Do<sup>1</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern; <sup>2</sup>Department of Nephrology, University Hospital of Alexandroupoli, Alexandroupoli, Greece; <sup>3</sup>Neurotune AG, 8952 Schlieren/ZH
- P 27**      **Food intake assessed by food dairy and PRODI6 analysis in Swiss Kidney stone formers: comparison to 24 hour urine excretion. NCCR project**  
**Nadia Ammor<sup>1</sup>**, **Nilufar Mohebbi<sup>2</sup>**, Daniel Fuster<sup>3</sup>, Thomas Hernandez<sup>4</sup>, Min Jeong Kim<sup>5</sup>, Beat Roth<sup>6</sup>, Grégoire Wuerzner<sup>1</sup>, Harald Seeger<sup>2</sup>, Nasser Dhayat<sup>3</sup>, Catherine Stoermann Chopard<sup>4</sup>, Michael Mayr<sup>5</sup>, Carsten Wagner<sup>7</sup>, Olivier Bonny<sup>8</sup>  
<sup>1</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>2</sup>Division of Nephrology, University Hospital Zurich, Zurich; <sup>3</sup>Division of Nephrology, Hypertension and Clinical Pharmacology, Department of Clinical Research, Institute of Biochemistry and Molecular Medicine and NCCR Transcure, University of Bern, Bern; <sup>4</sup>Service of Nephrology, University Hospital of Geneva, Geneva; <sup>5</sup>Clinic for Transplant Immunology and Nephrology, University Hospital Basel, Basel; <sup>6</sup>Clinic of Urology, Inselspital Bern, Bern; <sup>7</sup>Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich; <sup>8</sup>Department of Pharmacology and Toxicology, University of Lausanne, Lausanne

## Poster presentations

- P 28**      **Swiss Kidney Stone Cohort: first description of Swiss stone formers in 2014-2015. NCCR Project**  
**Olivier Bonny**<sup>1</sup>, Nilufar Mohebbi<sup>2</sup>, Daniel Fuster<sup>3</sup>, Thomas Hernandez<sup>4</sup>, Min Jeong Kim<sup>5</sup>, Beat Roth<sup>6</sup>, Grégoire Wuerzner<sup>7</sup>, Harald Seeger<sup>2</sup>, Nasser Dha-  
yat<sup>3</sup>, Catherine Stoermann Chopard<sup>4</sup>, Michael Mayr<sup>5</sup>, Carsten Wagner<sup>8</sup>  
<sup>1</sup>Department of Pharmacology and Toxicology, University of Laus-  
anne, Lausanne; <sup>2</sup>Division of Nephrology, University Hospital Zurich,  
Zurich; <sup>3</sup>Division of Nephrology, Hypertension and Clinical Pharma-  
cology, Department of Clinical Research, Institute of Biochemistry and  
Molecular Medicine and NCCR Transcure, University of Bern, Bern;  
<sup>4</sup>Service of Nephrology, University Hospital of Geneva, Geneva; <sup>5</sup>Clinic  
for Transplant Immunology and Nephrology, University Hospital Basel,  
Basel; <sup>6</sup>Clinic of Urology, Inselspital Bern, Bern; <sup>7</sup>Service of Nephrology  
and Hypertension, University Hospital Lausanne (CHUV), Lausanne;  
<sup>8</sup>Institute of Physiology, Zurich Centre for Integrative Human Physi-  
ology, University of Zurich, Zurich
- P 29**      **Impact of Renin-Angiotensin-Aldosterone blocking drugs in  
patients with Chronic Kidney Disease and superimposed communi-  
ty-acquired Acute Kidney Injury**  
**Cyrielle Alves**<sup>1</sup>, Belen Ponte<sup>1</sup>, Fabien Stucker<sup>2</sup>, Pierre-Yves Martin<sup>3</sup>, Thomas  
Hernandez<sup>1</sup>, Thomas Perneger<sup>4</sup>, Sébastien Carballo<sup>1</sup>, Patrick Saudan<sup>3</sup>  
<sup>1</sup>Service of General Internal Medicine, University Hospital of Geneva,  
Geneva; <sup>2</sup>Nephrology Unit, Hôpital de la Providence, Neuchâtel;  
<sup>3</sup>Nephrology Department, University Hospital of Geneva, Geneva; <sup>4</sup>Service  
of Clinical Epidemiology, University Hospital of Geneva, Geneva
- P 30**      **Endocrine Abnormalities Predisposing Autism Spectrum Disorders  
to Arterial Hypertension**  
**Benedikt Gasser**<sup>1</sup>, Bernhard Dick<sup>2</sup>, Johann Kurz<sup>3</sup>, Markus Mohaupt<sup>2</sup>  
<sup>1</sup>Institute of Physiology; University of Bern, Bern; <sup>2</sup>Department of  
Nephrology, Hypertension and Clinical Pharmacology, University  
Hospital and University of Bern, Inselspital, Bern; <sup>3</sup>Internal Medicine,  
Clinic Selgau, Selgau – Austria
- P 31**      **Devastating Anti-MPO Glomerulonephritis 14 Years After Autolo-  
gous Stem Cell Transplantation For Progressive Systemic Sclerosis**  
**Davide Spica**<sup>1</sup>, Ulrich Walker<sup>2</sup>, Bettina Bannert<sup>2</sup>, Ingmar Heijnen<sup>3</sup>,  
Andreas Bock<sup>1</sup>

## Poster presentations

<sup>1</sup>Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau ; <sup>2</sup>Rheumatology Division, Universitätsspital Basel, Basel ; <sup>3</sup>Immunology Division, Universitätsspital Basel, Basel

- P 32**      **Liver origin of erythropoietin during chronic kidney disease**  
**Sophie de Seigneux**<sup>1</sup>, Stine Lundby<sup>2</sup>, Patrick Saudan<sup>1</sup>, Pierre-Yves Martin<sup>1</sup>, Carsten Lundby<sup>2</sup>  
<sup>1</sup>Dept. of Nephrology, University Hospital of Geneva, Geneva ;  
<sup>2</sup>Institute of Physiology, University of Zurich, Zurich
- P 33**      **Rituximab in steroid- and calcineurin-inhibitor dependent minimal change disease in adults: Report of two cases**  
**Andrea Fisler**, Min Jeong Kim, Theresia Klima, Felix Burkhalter  
Clinic for Transplantation Immunology & Nephrology, University Hospital Basel, Basel
- P 34**      **SWIDINEP: a Swiss Cohort of patients with Diabetes and Nephropathy. Baseline characteristics.**  
**Menno Pruijm**<sup>1</sup>, Christiane Anex<sup>1</sup>, Nelly Pitteloud<sup>2</sup>, Michel Burnier<sup>1</sup>, Anne Zanchi<sup>2</sup>  
<sup>1</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne ; <sup>2</sup>Service of Endocrinology, Diabetes and Metabolism Service, University Hospital of Lausanne (CHUV), Lausanne
- P 35**      **Defect of complement regulatory proteins in a patient with HELLP syndrome and renal involvement**  
**Julia Wallner**<sup>1</sup>, Veronique Fremeaux-Bacchi<sup>2</sup>, Min Jeong Kim<sup>1</sup>  
<sup>1</sup>Clinic for Transplantation Immunology & Nephrology, University Hospital Basel, Basel ; <sup>2</sup>Service d'Immunologie Biologique, Hôpital Européen Georges-Pompidou, Paris, France
- P 36**      **Are hospitalised patients aged 90 years and over treated well for hypertension? Lessons from a prospective survey in a primary care hospital**  
**Jürgen Bohlender**<sup>1</sup>, Juerg Nussberger<sup>2</sup>, Beate Bohlender<sup>3</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Bern ; <sup>2</sup>Département de médecine et d'angiologie,

## Poster presentations

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne; <sup>3</sup>Medical clinic and general practice, Bernau b. B., Bern

P 37

### Stone composition of patients: data from laboratory

**Christine Deffert**<sup>1</sup>, Thomas Hernandez<sup>2</sup>, Catherine Stoermann Chopard<sup>2</sup>

<sup>1</sup>Department of Pathology and Immunology, Geneva University Hospitals, Geneva; <sup>2</sup>Service of Nephrology, University Hospital of Geneva, Geneva

## Basic science / Genetics / Experimental Nephrology

P 38

### Urinary metabolomic to identify new biomarkers of chronic kidney disease

**Belen Ponte**<sup>1</sup>, Nasim Bararpour<sup>2</sup>, Youssef Daali<sup>3</sup>, David Tonoli<sup>4</sup>, Julien Boccard<sup>2</sup>, Pierre Lescuyer<sup>5</sup>, Pierre-Yves Martin<sup>1</sup>, Serge Rudaz<sup>2</sup>, Sophie de Seigneux<sup>1</sup>

<sup>1</sup>Division of Nephrology, University of Geneva, Geneva; <sup>2</sup>School of Pharmaceutical Sciences, University of Geneva, Geneva; <sup>3</sup>Clinical Pharmacology and Toxicology Service, University Hospital of Geneva, Geneva; <sup>4</sup>Swiss Center for Applied Human Toxicology, University of Geneva, Geneva; <sup>5</sup>Division of Laboratory Medicine, University Hospital of Geneva, Geneva

P 39

### Integrated transcriptomic and proteomic analyses reveal the regulatory roles of nrf2 in the kidney (NCCR project)

**Adam Lister**<sup>1</sup>, Luke Shelton<sup>2</sup>, Joanne Walsh<sup>2</sup>, Rosalind Jenkins<sup>2</sup>, Michael Wong<sup>3</sup>, Cliff Rowe<sup>4</sup>, Emanuele Ricci<sup>5</sup>, Lorenzo Ressel<sup>5</sup>, Yongxiang Fang<sup>6</sup>, Philippe Demougins<sup>7</sup>, Vanja Vukojevic<sup>7</sup>, Paul O'Neill<sup>3</sup>, Christopher Goldring<sup>2</sup>, Neil Kitteringham<sup>2</sup>, Kevin Park<sup>2</sup>, Ian Copple<sup>2</sup>, Alex Odermatt<sup>1</sup>

<sup>1</sup>Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel; <sup>2</sup>MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; <sup>3</sup>Department of Chemistry, School of Physical Sciences, University of Liverpool, Liverpool, UK; <sup>4</sup>CN Bio Innovations Ltd, Centre for Innovation & Enterprise, Oxford University Begbroke Science Park, Oxford, UK; <sup>5</sup>School of Veterinary Science, University of Liverpool, Liverpool, UK; <sup>6</sup>Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, UK; <sup>7</sup>Department Biozentrum, Life Sciences Training Facility, University of Basel, Basel

## Poster presentations

- P 40**                    **Evaluation of rna extraction kits to enable rna sequencing of archival renal tissue**  
Lea Landolt<sup>1</sup>, Oystein Solberg Eikrem<sup>1</sup>, **Hans-Peter Marti**<sup>2</sup>  
<sup>1</sup>Department of Clinical Medicine, Nephrology, University of Bergen, Bergen, Norway; <sup>2</sup>Department of Pathology and Department of Clinical Medicine, Haukeland University Hospital and University of Bergen, Bergen, Norway
- P 41**                    **Siblings with two different rare genetic kidney diseases**  
**Milena Voskanyan**<sup>1,2</sup>, Marina Papazyan<sup>1</sup>, Nilufar Mohebbi<sup>3</sup>, Ariana Gaspert<sup>4</sup>, Ernst Leumann<sup>5</sup>, Ashot Sarkissian<sup>1,2</sup>  
<sup>1</sup>Nephrology Department, "Arabkir" Medical Centre, Yerevan, Armenia; <sup>2</sup>Yerevan State Medical University, Yerevan, Armenia; <sup>3</sup>Division of Nephrology, University Hospital Zurich, Zurich; <sup>4</sup>Institute of Surgical Pathology, University Hospital Zurich, Zurich; <sup>5</sup>University Children's Hospital, Zurich
- P 42**                    **The sodium/proton exchanger NHA2 is a novel regulator of sodium and calcium homeostasis in the distal convoluted tubule**  
**Manuel Anderegg**<sup>1</sup>, Giuseppe Albano<sup>1</sup>, Christine Deisl<sup>1</sup>, Ganesh Pathare<sup>1</sup>, Johannes Loffing<sup>2</sup>, Daniel Fuster<sup>1</sup>  
<sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and Department of Clinical Research and Institute of Biochemistry and Molecular Medicine, University of Bern, Bern; <sup>2</sup>Institute of Anatomy, University of Zurich, Zurich
- P 43**                    **Implementation of a "next generation sequencing- first" strategy for the diagnosis of genetic kidney disease in Switzerland: the Geneva experience (Ge-RenOME)**  
**Yassine Bouatou**<sup>1</sup>, Ariane Paoloni-Giacobino<sup>2</sup>, Pierre-Yves Martin<sup>1</sup>, Paloma Parvex<sup>3</sup>, Sophie de Seigneux<sup>1</sup>  
<sup>1</sup>Department of Nephrology, University Hospital of Geneva, Geneva; <sup>2</sup>Division of Medical Genetics, Geneva University Hospitals, Geneva; <sup>3</sup>Pediatric Nephrology Unit, Children's Hospital, Geneva University Hospitals, Geneva

## Poster presentations

- P 44**                    **Cross-talk between oxygen sensing and sodium handling in the collecting duct "NCCR project"**  
**Eva Dizin**<sup>1</sup>, Isabelle Roth<sup>1</sup>, Ian Frew<sup>2</sup>, Eric Feraille<sup>1</sup>  
<sup>1</sup>Department of Cellular Physiology and Metabolism, University of Geneva, Geneva; <sup>2</sup>Institute of Physiology, University of Zurich, Zurich
- P 45**                    **RNA Sequencing reveals Tumor Necrosis Factor  $\alpha$  Inducible Protein 6 (TNFAIP6) as a potential Single Gene Classifier of Renal Cell Carcinoma**  
 $\emptyset$ ystein Eikrem<sup>1</sup>, Lea Landolt<sup>1</sup>, Christian Beisland<sup>2</sup>, Anjana Shrestha<sup>1</sup>, Andreas Scherer<sup>3</sup>, **Hans-Peter Marti**<sup>4</sup>  
<sup>1</sup>Department of Medicine, Haukeland University Hospital and University of Bergen, Bergen, Norway; <sup>2</sup>Department of Urology, Haukeland University Hospital, Bergen, Norway; <sup>3</sup>Institute for Molecular Medicine Finland, Helsinki, Finland; <sup>4</sup>Department of Pathology and Department of Clinical Medicine, Haukeland University Hospital and University of Bergen, Bergen, Norway
- P 46**                    **Development and characterisation of a mass-spectrometric method for the quantification of uromodulin in human urine (NCCR)**  
**Thomas Hammond**<sup>1</sup>, Suzette Moes<sup>2</sup>, Sonia Youhanna<sup>3</sup>, Olivier Devuyst<sup>3</sup>, Alex Odermatt<sup>1</sup>, Paul Jenö<sup>2</sup>  
<sup>1</sup>Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel; <sup>2</sup>Proteomics Core Facility, Biozentrum, University of Basel, Basel; <sup>3</sup>Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich, Zurich
- P 47**                    **Reduced  $\beta$ -catenin levels promote cyst formation during fetal development (NCCR project)**  
**Stefan Rudloff**, Uyen Huynh-Do  
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern, Bern
- P 48**                    **Chronic hypoxia during fetal development induces renal cellular senescence (NCCR project)**  
**Stefan Rudloff**, Uyen Huynh-Do  
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern, Bern

## Poster presentations

### Hemodialysis / Peritoneal Dialysis

- P 49**      **A rare but shocking complication of haemodialysis**  
**Stefan Kalbermatter**, Denes Kiss  
Division of Nephrology, Kantonsspital Baselland, Liestal
- P 50**      **Automated peritoneal dialysis (apd) in systemic amyloidosis with amyloid infiltration of the peritoneum**  
Marianna De Francesco<sup>1</sup>, Silvio Pianca<sup>1</sup>, Giulia Bedino<sup>1</sup>, Tiziana Rusca Fadda<sup>2</sup>, Luca Giovannacci<sup>3</sup>, **Carlo Schönholzer**<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>2</sup>Cantonal Institute of Pathology, Clinical Pathology, Locarno; <sup>3</sup>Department of Surgery, Ospedale Regionale di Lugano, Lugano
- P 51**      **Calciophylaxis and haemodialysis: comorbidity or iatrogenicity?**  
**Samuele Rivolta**<sup>1</sup>, Sara De Marchi<sup>2</sup>, Olivier Giannini<sup>2</sup>, Giuseppe Bonforte<sup>1</sup>  
<sup>1</sup>Service of Nephrology, Ospedale Regionale di Mendrisio, Mendrisio; <sup>2</sup>Ospedale Regionale della Beata Vergine, Mendrisio, Mendrisio
- P 52**      **Challenge and limitations in the use of Slow Continuous Ultrafiltration (SCUF) with regional citrate anticoagulation (RCA) for refractory fluid overload**  
**Yimin Lu**<sup>1</sup>, Menno Pruijm<sup>1</sup>, Michel Burnier<sup>1</sup>, Roger Hullin<sup>2</sup>, Sébastien Kissling<sup>1</sup>  
<sup>1</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>2</sup>Service of Cardiology, University Hospital of Lausanne (CHUV), Lausanne
- P 53**      **Chronic dialysis, medication adherence and beliefs about medicines: a comparison between patients born in Switzerland and migrant patients (diana study)**  
**Jennifer Celio**<sup>1,2</sup>, Sabrina Maeder<sup>1</sup>, Georges Halabi<sup>3</sup>, Olivier Bugnon<sup>1,2</sup>, Menno Pruijm<sup>3\*</sup>, Marie-P. Schneider<sup>1,2\*</sup>  
\*Equal senior authors  
<sup>1</sup>Community pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva; <sup>2</sup>Community pharmacy, Department of ambulatory care & community medicine, University of Lausanne, Lausanne; <sup>3</sup>Service of Nephrology and Hypertension, Lausanne University Hospital (CHUV), Lausanne

## Poster presentations

- P 54**      **Preliminary results of dialysis study: single pool variable-volume calcium kinetic model**  
Salvatore Di Filippo<sup>1</sup>, Vincenzo La Milia<sup>1</sup>, **Fabio Carfagna<sup>1</sup>**,  
Claudio Minoretto<sup>2</sup>, Giuseppe Rombolà<sup>3</sup>, Carlo Schönholzer<sup>4</sup>, Giustina  
Casagrande<sup>5</sup>, Camilla Bianchi<sup>5</sup>, Maria Laura Costantino<sup>5</sup>, Giuseppe  
Pontoriero<sup>6</sup>, Francesco Locatelli<sup>1</sup>  
<sup>1</sup>Nephrology and Dialysis, A.O. Lecco, Lecco, Italy; <sup>2</sup>Nephrology and  
Dialysis, A.O. Sant'Anna, Como, Italy; <sup>3</sup>Nephrology and Dialysis,  
Ospedale di Circolo e Fondazione Macchi, Varese, Italy; <sup>4</sup>Regional  
Hospital of Lugano, Lugano; <sup>5</sup>Politecnico di Milano, Milano, Italy;  
<sup>6</sup>Alessandro Manzoni Hospital, Lecco, Italy
- P 55**      **"Sometimes peritoneal dialysis can last and last and last..." Two cases with a favorable long-term outcome**  
Anne Dschietzig, Vesna Reinmann, **Stefan Farese**  
Nephrology Department, Bürgerspital Solothurn, Solothurn
- P 56**      **Is alveolar-arterial pO<sub>2</sub> gradient using arterio-venous fistula sampling useful in estimating dryweight in dialysis patients?**  
**Eleonora Violetti<sup>1</sup>**, Alessandra Perna<sup>2</sup>, Silvio Pianca<sup>1</sup>, Lisa Pellegrini<sup>1</sup>,  
Carlo Schönholzer<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano;  
<sup>2</sup>Department of Cardiothoracic and Respiratory Sciences, Division of  
Nephrology, Seconda Università di Napoli, Napoli, Italy
- P 57**      **Pseudomonas exit site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics**  
**Felix Burkhalter<sup>1</sup>**, Michelle Clemenger<sup>2</sup>, San San Haddoub<sup>2</sup>, Jacqueline  
McGrory<sup>2</sup>, Nora Hisole<sup>2</sup>, Edwina Brown<sup>2</sup>  
<sup>1</sup>Transplantationsimmunology & Nephrology, University Hospital Basel,  
Basel; <sup>2</sup>Imperial College Renal and Transplant Centre, Hammersmith  
Hospital, London, UK
- P 58**      **Characteristics and outcome of migrant patients without a stable resident status starting hemodialysis in a Swiss university hospital center**  
**Thomas Hernandez**, Amalie Frandsen, Pierre-Yves Martin, Patrick Saudan  
Service of Nephrology, University Hospital of Geneva, Geneva



## Poster presentations

- P 59**                    **Association between mortality and glycemc control in a large Swiss hemodialysis cohort**  
**Danielle Creme**<sup>1</sup>, Rebecca Winzeler<sup>2</sup>, Hans-Rudolf Rätz<sup>3</sup>, Denes Kiss<sup>4</sup>, Thomas Kistler<sup>5</sup>, Agnes Kneubühl<sup>6</sup>, Marco Miozzari<sup>7</sup>, Patrice Ambühl<sup>2</sup>  
<sup>1</sup>Renal Division, Royal London Hospital, London, UK; <sup>2</sup>Institut für Nephrologie, Stadtspital Waid Zürich, Zürich; <sup>3</sup>Abteilung für Nephrologie, Kantonsspital Baden, Baden; <sup>4</sup>Division of Nephrology, Kantonsspital Baselland, Liestal; <sup>5</sup>Abteilung für Nephrologie, Kantonsspital Winterthur, Winterthur; <sup>6</sup>Abteilung für Nephrologie, Regionalspital Lachen, Lachen SZ; <sup>7</sup>Abteilung für Nephrologie, Kantonsspital Schaffhausen, Schaffhausen
- P 60**                    **Are our patients on hemodialysis at risk for scurvy?**  
**Michael Girsberger**, Michael Dickenmann, Felix Burkhalter, Min Jeong Kim, Theresia Klima  
Clinic for Transplantation Immunology & Nephrology, University Hospital Basel, Basel
- P 61**                    **Treatment satisfaction with renal replacement therapy in the frail elderly depends on recovery time after dialysis: Data from Frail Elderly Patients Outcomes on Dialysis (FEPOD) Study**  
**Felix Burkhalter**<sup>1</sup>, Osasuyi Iyasere<sup>2</sup>, Edwina Brown<sup>2</sup>  
<sup>1</sup>Transplantationsimmunology & Nephrology, University Hospital Basel, Basel; <sup>2</sup>Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, UK
- P 62**                    **Safety of Regional Citrate Anticoagulation during extended High Cut-Off hemodialysis for the clearance of serum free light chains: The Lausanne experience**  
**Sébastien Kissling**, Menno Pruijm, Michel Burnier, Daniel Teta  
Service of Nephrology and Hypertension, Department of Internal Medicine, University Hospital of Lausanne (CHUV), Lausanne
- P 63**                    **Statistical analysis of large amount of data aimed at the development of a index to predict intra-dialysis hypotensive events**  
**Domenico Vito**<sup>1</sup>, Giustina Casagrande<sup>1</sup>, Camilla Bianchi<sup>1</sup>, Carlo Schönholzer<sup>2</sup>, Giuseppe Pontoriero<sup>3</sup>, Maria Laura Costantino<sup>1</sup>  
<sup>1</sup>Politecnico di Milano, Milano, Italy; <sup>2</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>3</sup>Alessandro Manzoni Hospital, Lecco, Italy

## Poster presentations

- P 64**                    **Evaluation of the reliability of different methods for the determination of the hydration status in haemodialysis patients**  
**Giustina Casagrande<sup>1</sup>**, Camilla Bianchi<sup>1</sup>, Domenico Vito<sup>1</sup>, Elena Merlo<sup>1</sup>, Stefania Panzeri<sup>1</sup>, Giuseppe Pontoriero<sup>2</sup>, Carlo Schönholzer<sup>3</sup>, Maria Laura Costantino<sup>1</sup>  
<sup>1</sup>Politecnico di Milano, Milano, Italy; <sup>2</sup>Alessandro Manzoni Hospital, Lecco, Italy; <sup>3</sup>Regional Hospital of Lugano, Lugano
- P 65**                    **Peritoneal dialysis: training and peritonitis**  
**Hilary Riva<sup>1</sup>**, Gianna Croppi<sup>2</sup>, Emilia Arrighi<sup>3</sup>, Giannini Olivier<sup>4</sup>, Giuseppe Bonforte<sup>2</sup>  
<sup>1</sup>Nephrology Unit, Università Bicocca, Milano, Italy; <sup>2</sup>Service of Nephrology, Ospedale Regionale di Mendrisio; <sup>3</sup>Ospedale S. Anna, Como, Italy; <sup>4</sup>Ospedale Regionale della Beata Vergine, Mendrisio
- P 66**                    **Bloodstream infections and local access site infection surveillance program in hemodialysis, Vaud, Switzerland**  
**Delphine Héquet<sup>1</sup>**, Menno Pruijm<sup>2</sup>, Roberto Bullani<sup>3</sup>, Anne Cherpillod<sup>4</sup>, David Fumeaux<sup>4</sup>, Zina Fumeaux<sup>5</sup>, Thierry Gauthier<sup>6</sup>, Alfredo Guidetti<sup>7</sup>, Georges Halabi<sup>8</sup>, Olivier Phan<sup>9</sup>, Christiane Petignat<sup>1</sup>  
<sup>1</sup>Hygiene, Prevention and Infection Control Unit, Canton de Vaud and Preventive Medecine Service of CHUV, Lausanne; <sup>2</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>3</sup>Dialysis Center, EHC, Morges; <sup>4</sup>Dialysis Center, Clinique Cecil, Lausanne; <sup>5</sup>Hemodialysis Unit, Nyon Hospital, Nyon; <sup>6</sup>Hemodialysis Unit, Riviera Providence Hospital, Vevey; <sup>7</sup>Dialysis Center, Pays d'en Haut Hospital, Château d'Ëx; <sup>8</sup>Dialysis Center, EHN, Yverdon; <sup>9</sup>Dialysis Center, HIB, Payerne
- P 67**                    **Not everybody is created equal: Do we have a gender issue in the Swiss dialysis population?**  
**Rebecca Winzeler**, Patrice Ambühl  
Institut für Nephrologie, Stadtspital Waid Zürich, Zürich
- P 68**                    **The first hemodialysis unit in a nursing home in Switzerland: experience of the first 4 years**  
**Eleonora Violetti<sup>1</sup>**, Silvio Pianca<sup>1</sup>, Sergio Macchi<sup>2</sup>, Roberto Di Stefano<sup>2</sup>, Carlo Schönholzer<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>2</sup>Istituti Sociali Comunali di Lugano, Lugano

## Poster presentations

- P 69      **Demography of the Dialysis Population 2013 in Switzerland – The Swiss Dialysis Registry srqqap**  
**Rebecca Winzeler**, Patrice Ambühl  
Institut für Nephrologie, Stadtspital Waid Zürich, Zürich

## Transplantation

- P 70      **Belatacept-treated patients had superior estimated glomerular filtration rate (GFR) vs cyclosporine-treated patients: results from a mixed effects modeling analysis of BENEFIT**  
**Josep Grinyó**<sup>1</sup>, Lionel Rostaing<sup>2</sup>, Barbara Bresnahan<sup>3</sup>, Kim Rice<sup>4</sup>, Flavio Vincenti<sup>5</sup>, Martin Polinsky<sup>6</sup>, Ulf Meier-Kriesche<sup>6</sup>, Rafael Reyes-acevedo<sup>7</sup>, Jose Medina Pestana<sup>8</sup>  
<sup>1</sup>University Hospital Bellvitge, Barcelona, Spain; <sup>2</sup>University Hospital, and INSERM U563, IFR-BMT, Toulouse, France; <sup>3</sup>Medical College of Wisconsin, Milwaukee, WI, USA; <sup>4</sup>Baylor University Medical Center, Dallas, Texas, USA; <sup>5</sup>University of California, San Francisco, USA; <sup>6</sup>Bristol-Myers Squibb, USA; <sup>7</sup>Hospital Miguel Hidalgo de Aguascalientes, Aguascalientes, Mexico; <sup>8</sup>Hospital do Rim, Sao Paulo, Brasil
- P 71      **Acute humoral rejection after ABO incompatible transplantation successfully treated with bortezomib**  
**Katrin König**<sup>1</sup>, Helmut Hopfer<sup>2</sup>, Jörg Halter<sup>3</sup>, Lorenz Gürke<sup>4</sup>, Min Jeong Kim<sup>1</sup>, Jürg Steiger<sup>1</sup>, Patrizia Amico<sup>1</sup>  
<sup>1</sup>Clinic for Transplant Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Institute for Pathology, University Hospital Basel, Basel; <sup>3</sup>Division of Hematology, University Hospital Basel, Basel; <sup>4</sup>Department of Vascular and Transplant Surgery, University Hospital Basel, Basel
- P 72      **The Bernese Renal Osteometabolic Registry (RenOS) - A comprehensive approach of chronic kidney disease-mineral bone disorders (CKD-MBD) in renal transplant recipients**  
Larissa Garweg, Vasileios Devetziis, Uyen Huynh-Do,  
**Spyridon Arampatzis**  
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern

## Poster presentations

- P 73**      **Association of a common polymorphism of the ABCB1 gene (rs1045642) with bone mineral density and blood pressure at one year in a single center kidney transplant recipient cohort: intermediate analysis (supported by the Swiss Kidney Foundation)**  
**Yassine Bouatou**<sup>1</sup>, Ludwig Stenz<sup>2</sup>, Belen Ponte<sup>1</sup>, Serge Ferrari<sup>3</sup>, Pierre-Yves Martin<sup>1</sup>, Thierry Berney<sup>4</sup>, Ariane Paoloni-Giacobino<sup>5</sup>, Karine Hadaya<sup>1</sup>  
<sup>1</sup>Division of Nephrology, University Hospital of Geneva; <sup>2</sup>Department of Medical Genetics and Development, Group 923, University of Geneva; <sup>3</sup>Service of Bone Disease, Geneva University Hospitals, Geneva; <sup>4</sup>Division of Transplantation, Geneva University Hospitals, Geneva; <sup>5</sup>Division of Medical Genetics, Geneva University Hospitals, Geneva
- P 74**      **Rejection phenotypes in the current era of immunosuppression**  
**Caroline Wehmeier**<sup>1</sup>, Patricia Hirt-Minkowski<sup>1</sup>, Patrizia Amico<sup>1</sup>, Argyrios Georgalis<sup>1</sup>, Gideon Hönger<sup>1</sup>, Felix Burkhalter<sup>1</sup>, Michael Dickenmann<sup>1</sup>, Jürg Steiger<sup>1</sup>, Helmut Hopfer<sup>2</sup>, Stefan Schaub<sup>1</sup>  
<sup>1</sup>Department of Transplantation Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Institute for Pathology, University Hospital Basel, Basel
- P 75**      **Clinical significance of isolated v-lesions in kidney transplantation**  
**Patrizia Amico**, Argyrios Georgalis, Caroline Wehmeier, Patricia Hirt-Minkowski, Gideon Hoenger, Helmut Hopfer, Jürg Steiger, Stefan Schaub  
Transplantationsimmunology & Nephrology, University Hospital Basel, Basel
- P 76**      **Long-term survival outcomes in belatacept-treated vs cyclosporine-treated patients: final results from BENEFIT-EXT**  
**Antoine Durrbach**<sup>1</sup>, Robert Bray<sup>2</sup>, Howard Gebel<sup>2</sup>, Sander Florman<sup>3</sup>, Dirk Kuypers<sup>4</sup>, Christian P Larsen<sup>2</sup>, Jose Medina Pestana<sup>5</sup>, María Del Carmen Rial<sup>6</sup>, Lionel Rostaing<sup>7</sup>, Thomas Wekerle<sup>8</sup>, Ulf Meier-Kriesche<sup>9</sup>, Martin Polinsky<sup>9</sup>, Robert Townsend<sup>9</sup>, Josep Grinyó<sup>10</sup>  
<sup>1</sup>University Hôpital of Bicêtre, Bicêtre, France; <sup>2</sup>Emory University, Atlanta, Georgia, USA; <sup>3</sup>Mount Sinai Medical Center, New York, NY, USA; <sup>4</sup>University Hospitals Leuven, Leuven, Belgium; <sup>5</sup>Hospital do Rim, Sao Paulo, Bresil; <sup>6</sup>Instituto de Nefrología, Buenos Aires, Argentin

## Poster presentations

tina; <sup>7</sup>University Hospital, and INSERM U563, IFR-BMT, Toulouse, France; <sup>8</sup>Medical University of Vienna, Vienna, Austria; <sup>9</sup>Bristol-Myers Squibb, USA; <sup>10</sup>University Hospital Bellvitge, Barcelona, Spain

P 77

### **Control of blood pressure at 6, 12 and 24 months after kidney transplantation: data from the STCS**

**Yimin Lu**<sup>1</sup>, Dela Golshayan<sup>2</sup>, Pedro-Manuel Marques-Vidal<sup>3</sup>, Oriol Manuel<sup>2</sup>, Manuel Pascual<sup>2</sup>, Michel Burnier<sup>1</sup>, Grégoire Wuerzner<sup>1</sup>  
<sup>1</sup>Service of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne; <sup>2</sup>Transplantation Center, Department of Surgery, Lausanne University Hospital (CHUV), Lausanne; <sup>3</sup>Service of Internal Medicine, Lausanne University Hospital (CHUV), Lausanne; Swiss Transplant Cohort Study

P 78

### **Late onset Avascular Osteonecrosis: A debilitating complication with high prevalence among young renal transplant recipients**

Vasileios Devetzis, Anita Maurer, Uyen Huynh-Do,  
**Spyridon Arampatzis**  
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern

P 79

### **Evidence for a two-hit mechanism in mycophenolic acid-related chronic diarrhea in kidney transplant recipients**

**Seraina von Moos**, Pietro Cippà, Rudolf P. Wüthrich, Thomas Müller  
Division of Nephrology, University Hospital, Zurich, Zurich

P 80

### **A comparison of ATG-Fresenius® toThymoglobulin® induction therapy in immunological high-risk kidney recipients: a prospective randomized control trial**

**Felix Burkhalter**<sup>1</sup>, Stefan Schaub<sup>1</sup>, Christian Bucher<sup>2</sup>, Lorenz Gürke<sup>3</sup>, Alexander Bachmann<sup>4</sup>, Helmut Hopfer<sup>5</sup>, Michael Dickenmann<sup>1</sup>, Jürg Steiger<sup>1</sup>, Isabelle Binet<sup>2</sup>

<sup>1</sup>Transplantationsimmunology & Nephrology, University Hospital Basel, Basel; <sup>2</sup>Nephrology and Transplantation medicine, Kantonsspital St Gallen, St Gallen; <sup>3</sup>Department of Vascular and Transplant Surgery, University Hospital Basel, Basel; <sup>4</sup>Department of Urology, Basel University Hospital, Basel; <sup>5</sup>Institute for Pathology, University Hospital Basel, Basel

## Poster presentations

- P 81**                    **Impact of the new Swiss Organ Allocation System (SOAS) using calculated PRA and virtual crossmatching on clinical outcomes: first results from a single center**  
**Stefan Schaub**<sup>1</sup>, Gideon Hönger<sup>1</sup>, Urs Wirthmüller<sup>2</sup>, Vincent Aubert<sup>3</sup>, Kata Sunic<sup>4</sup>, Urs Schanz<sup>5</sup>, Franz Immer<sup>6</sup>, Jean-Marie Tiercy<sup>7</sup>, Jean Villard<sup>7</sup>  
<sup>1</sup>Clinic for Transplant Immunology and Nephrology, University Hospital Basel, Basel; <sup>2</sup>Inselspital Bern, Bern; <sup>3</sup>CHUV, Lausanne, Lausanne; <sup>4</sup>Kantonsspital, St. Gallen, St.Gallen; <sup>5</sup>Universitätsspital Zürich, Zurich; <sup>6</sup>SwissTransplant, Bern; <sup>7</sup>University Hospital of Geneva, Geneva
- P 82**                    **Prevention of Bone Mineral Density Loss in de novo Kidney Transplant Recipients with Twice-Yearly Denosumab: a Randomized Controlled Trial (ClinicalTrials.gov number NCT01377467)**  
**Marco Bonani**<sup>1</sup>, Diana Frey<sup>2</sup>, Jens Brockmann<sup>3</sup>, Thomas Fehr<sup>1</sup>, Thomas Müller<sup>1</sup>, Lanja Saleh<sup>4</sup>, Arnold von Eckardstein<sup>4</sup>, Nicole Graf<sup>5</sup>, Rudolf P. Wüthrich<sup>1</sup>  
<sup>1</sup>Division of Nephrology, University Hospital, Zurich; <sup>2</sup>Division of Rheumatology, University Hospital, Zurich; <sup>3</sup>Division of Visceral and Transplantation Surgery, University Hospital, Zurich; <sup>4</sup>Institute of Clinical Chemistry, University Hospital, Zurich; <sup>5</sup>Graf Biostatistics, Winterthur
- P 83**                    **The deleterious impact of a previously created AV-fistula on the radial bone in renal transplant recipients**  
Vasileios Devetzis, Anna Walder, **Uyen Huynh-Do**, Spyridon Arampatzis  
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, Bern
- P 84**                    **Unusual reddish-colored plasmapheresate: a case report**  
**Leano Violo**<sup>1</sup>, Marianna De Francesco<sup>1</sup>, Mauro Imperiali<sup>2</sup>, Silvio Pianca<sup>1</sup>, Carlo Schönholzer<sup>1</sup>  
<sup>1</sup>Division of Nephrology, Ospedale Regionale di Lugano, Lugano; <sup>2</sup>Department of laboratory medicine (EOLAB), Ospedale Regionale di Lugano, Lugano
- P 85**                    **CEUS guided management of compressive subcapsular hematoma after transplant kidney biopsy**  
**Florian Buchkremer**, Kurt Hodel, Andreas Bock  
Department of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau

## CONGRESS DINNER

19.30

Poster Prize Awards, Sponsored by ROCHE



& CONGRESS DINNER




In December of 2011, Käfer Schweiz AG took over the management of all catering services for all events at the Congress Center Basel and offers custom-tailored create concepts and excellent service. Their passion as a service provider and their love for detail in all aspects of the culinary trade make Käfer Schweiz AG the perfect partner to create the perfect culinary framework for our event.

We await your reservation with pleasure when registering online on [www.meeting-com.ch](http://www.meeting-com.ch). Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

Price: CHF 90.00/ticket

Congress Center Basel – Messeplatz 21, 4058 Basel

# Plan





# Exhibitors

<b>Firm</b>	<b>Booth</b>
Abbvie AG	14
Association pour l'information et la Recherche sur les maladies rénales Génétiques - AIRG	3
Alexion Pharma EMEA GmbH	10
Amgen Switzerland AG	17
Astellas Pharma AG	12
B. Braun Medical AG	11
Baxter AG	4
Bracco Suisse SA	8
Euromed Swiss AG	22
Forni medical gmbh	9
Fresenius Medical Care (Schweiz) AG	17
Laboratorium Dr G. Bichsel AG	20
MCM MEDSYS	24
Nationales Dialyseregister	2
Nipro D. Med Schweiz GmbH	16
Novartis Pharma Schweiz AG & Sandoz Pharmaceuticals AG	7
Novartis Oncology	1
OpoPharma Vertriebs AG	18
Otsuka Pharmaceutical (Switzerland) GmbH	15
Pro Farma AG	6
Salmon Pharma GmbH	21
Sanofi-Aventis Schweiz AG	5
Theramed AG	23
Vifor Pharma	13

# Sponsored symposia in alphabetical order



**Amgen Switzerland AG, Zug**  
Parallel Satellite Lunch Symposium  
Friday, December 4, 2015  
13.00-13.45 / Room A-Singapore



**Astellas Pharma AG, Wallisellen**  
Parallel Satellite Lunch Symposium  
Friday, December 4, 2015  
13.00-13.45 / Room B-Sydney



**Baxter AG, Volketswil**  
Parallel Satellite Lunch Symposium  
Thursday, December 3, 2015  
13.00-13.45 / Room B-Sydney

**Baxter AG, Volketswil**  
Parallel Satellite Symposium  
Friday, December 4, 2015  
12.00-12.45 / Room A-Singapore



**Novartis Oncology, Rotkreuz**  
Satellite Symposium  
Thursday, December 3, 2015  
17.15-18.15 / Room A-Singapore



**Otsuka Pharmaceutical (Switzerland) GmbH, Glattbrugg**  
Parallel Satellite Lunch Symposium  
Thursday, December 3, 2015  
13.00-13.45 / Room A-Singapore



**Vifor SA, Villars-sur-Glâne**  
Parallel Satellite Symposium  
Friday, December 4, 2015  
12.00-12.45 / Room B-Sydney

## Poster Prize Awards



**Roche Pharma (Schweiz) AG**

## Advertisement

Amgen Switzerland AG

Astellas Pharma AG

Baxter AG

Fresenius Medical Care (Schweiz) AG

Novartis Pharma Schweiz AG

Otsuka Pharmaceutical (Switzerland) GmbH

Vifor SA

## Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



*Kind thanks to the municipality of Basel for its financial support and welcome*



MUNICIPALITY  
BASEL

# Kind thanks to all our sponsors

abbvie

ALEXION™

AMGEN®

 astellas  
Leading Light for Life

**B | BRAUN**  
SHARING EXPERTISE

**Baxter**

  
**BRACCO**  
LIFE FROM INSIDE

 **EUROMED Swiss**  
Group Medical Distribution Services

*fm* *forni medical gmbh*

 **FRESENIUS  
MEDICAL CARE**

  
**bichsel**

 **MCM MEDSYS AG**

# Kind thanks to all our sponsors



*Salmon Pharma*  
Ein Unternehmen der



# Save the dates

## SGN-SSN CONGRESS 2016

48th Annual Meeting of the Swiss Society of Nephrology SGN-SSN  
on December 8-9, 2016 – Congress Centre Kursaal Interlaken



## SGN-SSN CONGRESS 2017

49th Annual Meeting of the Swiss Society of Nephrology SGN-SSN  
on December 7-8, 2017 – Forum Fribourg, Granges-Paccots



**NEPHRO**   
SWISS SOCIETY OF NEPHROLOGY

[www.swissnephrology.ch](http://www.swissnephrology.ch)

Schweizerische Gesellschaft für Nephrologie  
Société Suisse de Néphrologie  
Società Svizzera di Nefrologia

# こんにちは スイス\*



Otsuka ist ein weltweit agierendes Pharmaunternehmen mit Fokus auf der Entwicklung innovativer Arzneimittel und Medizinprodukte. Gemäss unserer japanischen Herkunft handeln wir nach der Philosophie des «Jissho-Shugi», was so viel heisst wie «Überzeugen durch Taten». Ein Grundsatz, mit dem wir den Schweizer Markt beleben.

\*Konichiwa/Hallo Schweiz



Otsuka-people creating new products for better health worldwide

**Otsuka Pharmaceutical (Switzerland) GmbH**  
Sägereistrasse 20, CH-8152 Glattbrugg  
Phone: +41 43 211 61 11 Fax: +41 43 211 61 10  
[www.otsukaswitzerland.ch](http://www.otsukaswitzerland.ch)



## Die Kunst der sHPT-Kontrolle

Durch die gleichzeitige Senkung aller drei biochemischen Schlüsselparameter (PTH, Kalzium und Phosphat),<sup>1,2</sup> verbessert Mimpara® die Kontrolle des sekundären Hyperparathyreoidismus (sHPT).<sup>3-5</sup>

Mimpara®  
cinacalcet

**Mimpara® (Cinacalcet):** Calcimimetikum. Es senkt direkt die Parathormonspiegel indem es die Empfindlichkeit des Kalziumsensitiven-Rezeptors auf extrazelluläres Kalzium erhöht. Die Reduktion der Parathormonspiegel ist mit einer gleichzeitigen Abnahme der Serumkalziumspiegel verbunden. **Indikationen:** Zur Behandlung von sekundärem Hyperparathyreoidismus bei dialysepflichtigen Patienten mit chronischer Nierenerkrankung. Zur Behandlung der Hyperkalzämie bei Patienten mit Nebenschilddrüsenkarzinom und bei Patienten mit primärem Hyperparathyreoidismus, bei denen die Entfernung der Nebenschilddrüse keine Behandlungsmöglichkeit darstellt. **Dosierung/Anwendung:** Mimpara® wird oral gegeben. PHPT: Empfohlene Anfangsdosis für Erwachsene ist 30mg zweimal täglich. Die Dosis von Mimpara® kann ausgehend von zweimal täglich 30mg, alle 2-4 Wochen auf 60mg zweimal täglich, 90mg zweimal täglich, bis zu 90mg 3-4x täglich erhöht werden, abhängig von der Normalisierung der Serumkalziumspiegel. Der Serumkalziumspiegel sollte innerhalb der ersten Woche nach Beginn der Therapie oder Dosisanpassung von Mimpara® gemessen werden. Nachdem die Erhaltungsdosis festgelegt wurde, sollte der Serumkalziumspiegel alle 2-3 Monate gemessen werden. sHPT: Empfohlene Anfangsdosis für Erwachsene ist 30mg einmal täglich. Alle 2-4 Wochen aufzutitrieren, bis zur Erreichung des iPTH Zielwert von 150-300pg/ml. Serumkalziumspiegel während der Titrationsphase häufig, in der Erhaltungssphase monatlich kontrollieren. Parathormon 1-4 Wochen nach Therapiebeginn oder Dosisanpassung messen, in der Erhaltungssphase alle 1-3

Monate kontrollieren. **Kontraindikationen:** Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe gemäss Zusammensetzung. **Warnhinweise und Vorsichtsmassnahmen:** Anfälle: Die Schwelle für die Auslösung von Anfällen ist bei einer signifikanten Reduktion der Serumkalziumspiegel herabgesetzt. Serumkalzium: Da Cinacalcet die Serumkalziumspiegel erniedrigt, sollten Patienten auf Hypokalzämiesymptome überwacht werden. Fälle von QT-Verlängerung und ventrikulärer Arrhythmie sekundär zu einer Hypokalzämie wurden angegeben. Bei mit Mimpara® behandelten Patienten, einschliesslich pädiatrischen Patienten, wurde im Zusammenhang mit Hypokalzämie von lebensbedrohlichen Ereignissen und Todesfällen berichtet. Der Serumkalziumspiegel sollte innerhalb von 1 Woche nach dem Beginn der Behandlung oder einer Dosisanpassung von Mimpara® gemessen werden. Wenn die Erhaltungsdosis eingestellt ist, sollte das Serumkalzium ungefähr monatlich bestimmt werden. Bei Hypokalzämie sollten geeignete Massnahmen gemäss vollständiger Fachinformation ergriffen werden. Falls die PTH-Spiegel bei mit Mimpara® behandelten Patienten tiefer als die unteren empfohlenen Zielwerte sinken, sollten die Dosierung der Vitamin-D-Sterole oder von Mimpara® reduziert bzw. die Behandlung abgebrochen werden. **Interaktionen:** Ketoconazol: Cinacalcet wird teilweise durch das Enzym CYP3A4 metabolisiert. Die gleichzeitige Verabreichung von Ketoconazol resultiert in einer ungefähr 2fachen Erhöhung der Cinacalcet-Spiegel. Arzneistoffe, die durch CYP2D6 metabolisiert werden: Es konnten keine Interaktionen beobachtet werden, wenn

Mimpara® gleichzeitig mit folgenden Arzneimitteln zusammen gegeben wurde: Sevelamer, Kalziumkarbonat, Warfarin und Pantoprazol. **Unerwünschte Wirkungen:** Immunsystem: Häufig: Hypersensitivitätsreaktionen. Stoffwechsel und Ernährung: Häufig: Anorexie, verminderter Appetit, Hypokalzämie. Nervensystem: Häufig: Krampfanfälle, Schwindel, Parästhesien, Kopfschmerzen. Gefässe: Häufig: Hypotonie. Atmungsorgane: Häufig: Infektion der oberen Atemwege, Dyspnoe, Husten. Gastrointestinaltrakt: Sehr häufig: Übelkeit, Erbrechen. Haut: Häufig: Rash. Muskelskelettsystem: Sehr häufig: Muskelspasmen. Allgemeine Erkrankungen: Häufig: Asthenie. Untersuchungen: Häufig: Hypokalzämie, Hyperkalzämie, verringerte Testosteronwerte. **Packungen:** Filmtabletten mit 30, 60 und 90mg Mimpara® in Blisterpackungen à 28 Stück. Ausführliche Angaben entnehmen Sie bitte der Fachinformation unter [www.swissmedinfo.ch](http://www.swissmedinfo.ch). **Zulassungsinhaber:** Amgen Switzerland AG, Zug. **Verkaufskategorie B.** MN-CHE-AMG-321-2014-December-P

### Referenzen:

1. Messa P et al. Clin J Am Soc Nephrol 2008;3(1):36-45.
2. Frazão JM et al. Clin Nephrol 2011; 76(3): 233-243.
3. Ureña-Torres PA et al. Nephrol Dial Transplant 2013; 28(1): 146-152.
4. The EVOLVE trial investigators. N Engl J Med 2012;367(26):2482-2494.
5. Block G et al. Kidney Int. 2010; 78:578-589.

AMGEN Switzerland AG, Dammstrasse 21  
6301 Zug, [www.amgen.ch](http://www.amgen.ch)